Topical liquid agent of the treatment of dermatophytosis

LAP345AUndetermined Publication Date: 2026-02-27MEIJI SEIKA KAISHA LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
LAP345
Authority / Receiving Office
LA · LA
Patent Type
Applications
Current Assignee / Owner
Priority Date
2012-07-30
Filing Date
2013-07-30
Publication Date
2026-02-27

Smart Images

  • Figure P%2F345_DRAWING_001
    Figure P%2F345_DRAWING_001
Patent Text Reader

Abstract

According to the present invention, a topical liquid agent having antifungal activity against dermatophytes, and further high nail permeability can be provided. A topical liquid agent for a nail and / or skin for prevention or treatment of dermatophytosis comprises a film-forming agent and a compound represented by the formula: wherein R1 represents hydrogen atom, C1-6 alkyl, or trifluoromethyl, R2 represents hydrogen atom, C1-6 alkyl, halogen, —COO(C1-6 alkyl), or (CH2)1-3COOR where R represents hydrogen atom or C1-6 alkyl, R3 represents hydrogen atom, C1-6 alkyl, amino, trifluoromethyl, or OR where R represents hydrogen atom or C1-6 alkyl, R4 represents hydroxyl group, R5represents hydrogen atom, C1-6 alkyl, a hydroxyl group, or halogen, R6 represents a hydrogen atom , C1-6 alkyl, trifluoromethyl, halogen, amino, —NRaRb, nitro, hydroxy-C1-6 alkyl, —CONRaRb, —COO(C1-6 alkyl), —COOH, —(CH2)1-3COOR, or ORa where R represents hydrogen atom or C1-6 alkyl, Ra and Rb may be the same or different from each other, and each represent a hydrogen atom, C1-6 alkyl, or C1-6 acyl, R7 represents a hydrogen atom, C1-6 alkyl, —OR where R represents a hydrogen atom or C1-6 alkyl, or halogen, R8 represents a hydrogen atom, C1-6 alkyl, a hydroxyl group, amino, or nitro, or a salt thereof.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] The present invention relates to a topical solution for the prevention or treatment of dermatophytosis, comprising a novel 2-(1H-pyrazole-1-yl)phenol derivative or a pharmaceutically acceptable salt thereof, which is suitable as an anti-dermatophyte agent, as an active ingredient.

[0002] Mycoses are diseases caused by fungal infections in humans or animals. Representative mycoses in humans include candidiasis caused by Candida, cryptococcosis caused by Cryptococcus, aspergillosis caused by Aspergillus, zygomycosis caused by Zygomycetes, and dermatophytosis (tinea) caused by Trichophyton (Pathogenic Fungi and Mycoses (Nanzando, Revised 2nd Edition), pp. 42-45; Non-Patent Literature 1).

[0003] Trichophyton, one of the pathogens of mycoses, is a dermatophyte that can cause ringworm and possesses the property of keratinogenesis. This ability allows it to invade the skin, nails, and hair and cause ringworm (Pathogenic Fungi and Mycoses (Nanzando, Revised 2nd Edition), pp. 184-187; Non-Patent Literature 2).

[0004] Onychomycosis is a nail disease caused by dermatophytes, which are said to account for more than 90% of onychomycosis cases in Japan. It is characterized by symptoms such as clouding, thickening, destruction, and deformation of the nail plate. Currently, it is estimated that one in ten Japanese people, or about 12 million people, suffer from this disease. It is a disease that is common in the elderly, and there are concerns that the number of patients will increase further in the future. In addition, there are reports that people with diabetes are more susceptible to it, and it has been pointed out that it may cause serious complications.

[0005] Currently in Japan, the only approved treatment for onychomycosis is oral antifungal medication (such as itraconazole and terbinafine). However, oral antifungal medications have been associated with drug interactions, liver damage, and side effects from long-term administration. Furthermore, elderly individuals and diabetic patients, who have a high incidence of onychomycosis, often take multiple medications, making oral administration of antifungal drugs for the treatment of onychomycosis difficult in many cases (Br. J. of Dermatol., vol.139(4), p665, 1998; Non-Patent Literature 3).

[0006] Regarding topical antifungal agents, in order for topical antifungal agents to exert their therapeutic effect, the drug itself must have strong antifungal activity, and it is also necessary to deliver a high concentration of the drug to the infected area, the stratum corneum of the epidermis and the nail. However, topical antifungal agents used for typical skin fungal infections cannot reach the keratin, interior, and nail bed of the nail at a sufficient concentration, and therefore do not provide sufficient efficacy.

[0007] Topical nail lacquers containing amorolfine and cyclopirox are approved and used overseas. However, their penetration into the nail is very low, and it is not expected that they will penetrate and reach the nail matrix cells.

[0008] For this reason, topical solutions for tinea infections such as onychomycosis need to have not only strong antifungal activity but also high permeability to the nail, but such a topical solution has not yet been found.

[0009] On the other hand, as a compound having a 2-(1H-pyrazole-1-yl)phenol skeleton, 2-(3,5-dimethyl-1H-pyrazole-1-yl)phenol, which has methyl groups at the 3rd and 5th positions of the pyrazole ring, is known (Takeda Research Institute Annual Report (1963) 22, p27; Non-Patent Literature 4). These are intended to inhibit the growth of Mycobacterium tuberculosis. However, Non-Patent Literature 4 does not disclose any 2-(1H-pyrazole-1-yl)phenol compounds other than 2-(3,5-dimethyl-1H-pyrazole-1-yl)phenol.

[0010] Besides 2-(3,5-dimethyl-1H-pyrazole-1-yl)phenol, other compounds having a 2-(1H-pyrazole-1-yl)phenol skeleton include 2-(1H-pyrazole-1-yl)phenol, 2-(3,5-dimethyl-1H-pyrazole-1-yl)-1,4-benzenediol, and 2-(4-chloro-3,5-dimethyl-1H-pyrazole-1-yl)-1,4-benzenediol. These are used in various chemical reactions and as raw materials for electroluminescent element compounds (Patent No. 4284169: Patent Document 1), and as light stabilizers (Spanish Publication No. 20158648: Patent Document 2). In addition, WO2003 / 005999 (Patent Document 3) discloses 2-(5-amino-3-tert-butyl-1H-pyrazole-1-yl)-5-methylphenol.

[0011] However, these prior art documents do not offer any suggestions or disclosures regarding the anti-dermatophyte activity of compounds having a 2-(1H-pyrazole-1-yl)phenol skeleton.

[0012] Japanese Patent No. 4284169, Spanish Publication No. 20158648, WO2003 / 005999

[0013] Pathogenic fungi and mycoses (Nanzando, revised 2nd edition), p42-45 Pathogenic fungi and mycoses (Nanzando, revised 2nd edition), p184-187Br. J. of Dermatol., vol.139(4), p665, 1998 Takeda Research Institute Annual Report (1963) 22, p27

[0014] As described above, there is a strong need for topical solutions for superficial fungal infections such as onychomycosis that not only have antifungal activity but also have high permeability to the nail. Therefore, the object of the present invention is to provide a topical solution for nails and / or skin that has antifungal activity and also has high nail permeability.

[0015] The present inventors have found that topical solutions containing compounds having a 2-(1H-pyrazole-1-yl)phenol skeleton represented by the following formula (I), or salts and polymers thereof, form a film when applied to the nails and / or skin, and have high nail permeability, high storage stability, and high anti-dermatophyte activity, as well as an inhibitory effect on drug precipitation. Based on these findings, the present invention was completed.

[0016] That is, the present invention relates to a film-forming agent and a general formula (wherein R 1 represents a hydrogen atom, C 1-6 alkyl, or trifluoromethyl, R 2 represents a hydrogen atom, C 1-6 alkyl, halogen, -COO(C 1-6 alkyl), or (CH 2 ) 1-3 COOR (R represents a hydrogen atom or C 1-6 alkyl), R 3 represents a hydrogen atom, C 1-6 alkyl, amino, trifluoromethyl, or OR (R represents a hydrogen atom or C 1-6 alkyl), R 4 represents a hydroxyl group, R 5 represents a hydrogen atom, C 1-6 alkyl, a hydroxyl group, or halogen, R 6 represents a hydrogen atom, C 1-6 alkyl, trifluoromethyl, halogen, amino, -NR a R b [[ID=五十一]]、ニトロ、ヒドロキシC 1-6 アルキル、-CONR a R b 、-COO(C 1-6 アルキル)、-COOH、-(CH 2 ) 1-3 COOR、またはOR a (Rは、水素原子またはC 1-6 アルキルを表し、R a およびR b は、同一でも異なっていてもよく、水素原子、C 1-6 アルキル、またはC 1-6 アシルを表す)、 R 7 は、水素原子、C 1-6 アルキル、-OR(Rは、水素原子またはC 1-6 アルキルを表す)、またはハロゲンを表して、 R8 C is a hydrogen atom. 1-6 The present invention relates to a topical solution for nails and / or skin for the prevention or treatment of tinea infection, comprising a compound represented by (which represents an alkyl, hydroxyl, amino, or nitro group) or a salt thereof.

[0017] The topical solution of the present invention not only exhibits high antifungal activity against dermatophytes, but also has high permeability to nails, and is therefore useful as a topical solution for nails and / or skin for the prevention or treatment of dermatophytosis, especially onychomycosis.

[0018] Terms used herein include "C 1-6 "alkyl", part of the group "C" 1-6 "Alkyl" refers to an alkyl group having 1 to 6 carbon atoms. This alkyl group may be linear, branched, or cyclic. Examples include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, hexyl, etc. 1-6 C such as alkyl groups, cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl 3-6 Examples include cycloalkyl groups.

[0019] Terms used herein include "C 1-6 "Ashiru", part of the base "C" 1-6 "Acyl" refers to an acyl group having 1 to 6 carbon atoms. This acyl group may be linear, branched, or cyclic. Examples include formyl, acetyl, propionyl, butyryl, and isobutyryl. Preferably, examples include formyl, acetyl, propionyl, and butyryl.

[0020] As used herein, "halogen" refers to fluorine, chlorine, bromine, iodine, and the like.

[0021] The group or part of a group used herein, "-OR (R is a hydrogen atom or C)", is a group or part of a group used herein. 1-6 The character "alkyl" represents a hydroxyl group, or C 1-6 This represents alkyloxy. Here, "C 1-6 "alkyl" is the same as the "C 1-6 It is synonymous with "alkyl".

[0022] "-OR" is a group or part of a group used herein. a In ", Ra C is a hydrogen atom. 1-6 Alkyl, or C 1-6 Represents acile, "-OR a " is a hydroxyl group, C 1-6 Alkyloxy, or C 1-6 This represents acyloxy. Here, "C 1-6 "alkyl" is the same as the "C 1-6 It is synonymous with "alkyl".

[0023] Regarding compounds of general formula (I) or their salts and solvates As described above, the present invention relates to a film-forming agent and a general formula The present invention relates to a topical solution for nails and / or skin for the prevention or treatment of tinea infection, comprising a compound represented by or a salt thereof.

[0024] In general formula (I), R 1 C is a hydrogen atom. 1-6 Represents alkyl or trifluoromethyl, preferably a hydrogen atom or C 1-6 It is alkyl, and more preferably C 1-6 It is alkyl. 1 Specifically, examples include hydrogen atoms, methyl atoms, and ethyl atoms.

[0025] In general formula (I), R 2 C is a hydrogen atom. 1-6 Alkyl, halogen, -COO(C) 1-6 Alkyl), or -(CH 2 ) 1-3 COOR (where R is a hydrogen atom or C) 1-6 Represents alkyl, preferably a hydrogen atom, C 1-6 Represents alkyl or halogen. 2 Specifically, examples include hydrogen atoms, methyl, ethyl, propyl, butyl, chlorine atoms, or 2-carboxyethyl.

[0026] In general formula (I), R 3 C is a hydrogen atom. 1-6 Alkyl, amino, trifluoromethyl, -OR (where R is a hydrogen atom or C) 1-6 Represents an alkyl group, preferably a hydrogen atom or C 1-6 Represents alkyl, and more preferably C 1-6represents an alkyl group. R 3 Specific examples of R include methyl or ethyl.

[0027] In general formula (I), R 4 represents a hydroxyl group.

[0028] In general formula (I), R 5 represents a hydrogen atom, C 1-6 alkyl, a hydroxyl group, or a halogen, preferably a hydrogen atom.

[0029] In general formula (I), R 6 represents a hydrogen atom, C 1-6 alkyl, trifluoromethyl, a halogen, an amino group, -NR a R b , a nitro group, hydroxy C 1-6 alkyl, -CONR a R b , -COO(C 1-6 alkyl), -COOH, -(CH 2 ) 1-3 COOR, or OR a (where R represents a hydrogen atom or C 1-6 alkyl, and R a and R b may be the same or different and represent a hydrogen atom, C 1-6 alkyl, or C 1-6 acyl), preferably a hydrogen atom, C 1-6 alkyl, trifluoromethyl, a halogen, an amino group, -NR a R b , a nitro group, hydroxy C 1-6 alkyl, -CONR a R b , -COOH, or OR a (where R a and R b may be the same or different and represent a hydrogen atom, C 1-6 alkyl, or C 1-6 acyl), more preferably a hydrogen atom, C 1-6 alkyl, a halogen, or OR a (where R a represents a hydrogen atom, C 1-6 alkyl, or C 1-6 acyl), R 6 6Specifically, examples include hydrogen atoms, methyl, ethyl, methoxy, chlorine atoms, bromine atoms, fluorine atoms, hydroxyl groups, acetoxy, amino, nitro, carboxyl, hydroxymethyl, trifluoromethyl, methylamino, carbamoyl, or N,N-dimethylcarbamoyl.

[0030] R 7 C is a hydrogen atom. 1-6 Alkyl, -OR (where R is a hydrogen atom or C) 1-6 (representing alkyl), or halogen, preferably representing a hydrogen atom.

[0031] R 8 C is a hydrogen atom. 1-6 Represents alkyl, hydroxyl, amino, or nitro, preferably a hydrogen atom, C 1-6 R represents alkyl, amino, or nitro, and more preferably represents a hydrogen atom. 8 Specifically, these include hydrogen atoms, methyl atoms, nitro atoms, or amino atoms.

[0032] In the topical solution for nails and / or skin for the prevention or treatment of tinea infection of the present invention, preferred compounds of general formula (I) are: R 1 However, hydrogen atoms or C 1-6 It is alkyl, R 2 However, hydrogen atoms, C 1-6 Alkyl, halogen, or -(CH 2 ) 1-3 COOR (where R is a hydrogen atom or C) 1-6 (represents alkyl) R 3 However, hydrogen atoms, or C 1-6 It is alkyl, R 4 However, it is a hydroxyl group, R 5 However, it is a hydrogen atom, R 6 However, hydrogen atoms, C 1-6 Alkyl, trifluoromethyl, halogen, amino, -NR a R b nitro, hydroxy C 1-6 Alkyl, -CONR a R b, -COOH, or OR a (R a and R b They may be the same or different, and include hydrogen atoms and C 1-6 Alkyl, or C 1-6 (represents acyl) R 7 However, it is a hydrogen atom, R 8 However, hydrogen atoms, C 1-6 The compound is alkyl, amino, or nitro (corresponding to claim 2).

[0033] In the topical solution for nails and / or skin for the prevention or treatment of tinea infection of the present invention, a more preferred compound of general formula (I) is: R 1 However, C 1-6 It is alkyl, R 2 However, hydrogen atoms, C 1-6 Alkyl or halogen, R 3 However, C 1-6 It is alkyl, R 4 However, it is a hydroxyl group, R 5 However, it is a hydrogen atom, R 6 However, hydrogen atoms, C 1-6 Alkyl, halogen, or OR a (R a C is a hydrogen atom. 1-6 Alkyl, or C 1-6 (represents acyl) R 7 However, it is a hydrogen atom, R 8 However, it is a compound that is a hydrogen atom (corresponding to claim 3).

[0034] In the topical solution for nails and / or skin for the prevention or treatment of tinea infection of the present invention, a more preferred compound of general formula (I) is R 1 However, C 1-6 It is alkyl, R 2 However, it is a hydrogen atom, R 3 However, C 1-6 It is alkyl, R 4However, it is a hydroxyl group, R 5 However, it is a hydrogen atom, R 6 However, C 1-6 It is alkyl, R 7 However, it is a hydrogen atom, R 8 However, it is a compound that is a hydrogen atom (corresponding to claim 4).

[0035] Examples of compounds of general formula (I) contained in the nail and / or skin topical solution for the prevention or treatment of tinea infection of the present invention include the following compounds. Manufacturing Example 1: 2-(3,5-dimethyl-1H-pyrazole-1-yl)phenol Manufacturing Example 2: 2-(3,5-dimethyl-1H-pyrazole-1-yl)-4-fluorophenol Manufacturing Example 3: 2-(1H-pyrazole-1-yl)phenol Manufacturing Example 4: 2-(5-hydroxy-3-methyl-1H-pyrazole-1-yl)phenol Manufacturing Example 5: 2-(5-methyl-3-trifluoromethyl-1H-pyrazole-1-yl)phenol Manufacturing Example 6: 2-(3,5-bistrifluoromethyl-1H-pyrazole-1-yl)phenol Manufacturing Example 7: 2-(3-methyl-1H-pyrazole-1-yl)phenol Manufacturing Example 8: 2-(5-methyl-1H-pyrazole-1-yl)phenol Manufacturing Example 9: 2-(3,4,5-trimethyl-1H-pyrazole-1-yl)phenol Manufacturing Example 10: 2-(5-amino-3-tert-butyl-1H-pyrazole-1-yl)phenol Manufacturing Example 11: 4-Chloro-2-(3,5-dimethyl-1H-pyrazole-1-yl)phenol Manufacturing Example 12: 2-Chloro-6-(3,5-dimethyl-1H-pyrazole-1-yl)phenol Manufacturing Example 13: 2-(4-chloro-3,5-dimethyl-1H-pyrazole-1-yl)phenol Manufacturing Example 14: 2-(3,5-diethyl-1H-pyrazole-1-yl)phenol Manufacturing Example 15: 3-(3,5-dimethyl-1H-pyrazole-1-yl)benzene-1,2-diol Manufacturing Example 16: 2-(3,5-dimethyl-1H-pyrazole-1-yl)benzene-1,4-diol Manufacturing Example 17: 2-(4-ethyl-3,5-dimethyl-1H-pyrazole-1-yl)phenol Manufacturing Example 18: 5-Fluoro-2-(3,4,5-trimethyl-1H-pyrazole-1-yl)phenol Manufacturing Example 19: 2-(4-chloro-3,5-dimethyl-1H-pyrazole-1-yl)benzene-1,4-diol Manufacturing Example 20: 4-Fluoro-2-(3,4,5-trimethyl-1H-pyrazole-1-yl)phenol Manufacturing Example 21: 2-(4-chloro-3,5-dimethyl-1H-pyrazole-1-yl)-5-fluorophenol Manufacturing Example 22: 1-(2-hydroxyphenyl)-3,5-dimethyl-1H-pyrazole-4-carboxylate ethyl Manufacturing Example 23: 3-(1-(2-hydroxyphenyl)-3,5-dimethyl-1H-pyrazole-4-yl)methyl propanoate Manufacturing Example 24: 2-(4-butyl-3,5-dimethyl-1H-pyrazole-1-yl)phenol Manufacturing Example 25: 2-(3,5-dimethyl-1H-pyrazole-1-yl)-5-fluorophenol Manufacturing Example 26: 5-Chloro-2-(3,5-dimethyl-1H-pyrazole-1-yl)phenol Manufacturing Example 27: 2-(3,5-dimethyl-1H-pyrazole-1-yl)-3-nitrophenol Manufacturing Example 28: 2-(3,5-dimethyl-1H-pyrazole-1-yl)-5-nitrophenol Manufacturing Example 29: 3-(1-(2-hydroqiphenyl)-3,5-dimethyl-1H-pyrazole-4-yl)propionic acid Manufacturing Example 30: 5-Chloro-2-(3,4,5-trimethyl-1H-pyrazole-1-yl)phenol Manufacturing Example 31: 5-amino-2-(3,5-dimethyl-1H-pyrazole-1-yl)phenol Manufacturing Example 32: 5-Nitro-2-(3,4,5-trimethyl-1H-pyrazole-1-yl)phenol Manufacturing Example 33: 4-(3,5-dimethyl-1H-pyrazole-1-yl)benzene-1,3-diol Manufacturing Example 34: 5-amino-2-(3,4,5-trimethyl-1H-pyrazole-1-yl)phenol Manufacturing Example 35: 4-(3,5-dimethyl-1H-pyrazole-1-yl)-3-hydroxybenzenecarboxylate methyl Manufacturing Example 36: 3-amino-2-(3,5-dimethyl-1H-pyrazole-1-yl)phenol Manufacturing Example 37: 4-(3,5-dimethyl-1H-pyrazole-1-yl)-3-hydroxybenzenecarboxylic acid Manufacturing Example 38: 4-(3,5-dimethyl-1H-pyrazole-1-yl)-3-hydroxy-N,N-dimethylbenzamide Manufacturing Example 39: 4-(3,5-dimethyl-1H-pyrazole-1-yl)-3-hydroxybenzamide Manufacturing Example 40: 3-Hydroxy-4-(3,4,5-trimethyl-1H-pyrazole-1-yl)benzenecarboxylic acid Manufacturing Example 41: 3-Hydroxy-4-(3,4,5-trimethyl-1H-pyrazole-1-yl)benzamide Manufacturing Example 42: 4-(4-chloro-3,5-dimethyl-1H-pyrazole-1-yl)-3-hydroxybenzamide Manufacturing Example 43: 2-(3,5-dimethyl-1H-pyrazole-1-yl)benzene-1,3-diol Manufacturing Example 44: 2-(3,5-dimethyl-1H-pyrazole-1-yl)-5-methylphenol Manufacturing Example 45: 2-(3,5-dimethyl-1H-pyrazole-1-yl)-5-methoxyphenol Manufacturing Example 46: 2-(3,5-dimethyl-1H-pyrazole-1-yl)-3-methylphenol Manufacturing Example 47: 2-(3,5-dimethyl-1H-pyrazole-1-yl)-5-hydroxymethylphenol Manufacturing Example 48: 2-(3,5-dimethyl-1H-pyrazole-1-yl)-5-methylaminophenol Manufacturing Example 49: 2-(3,5-dimethyl-1H-pyrazole-1-yl)-4-methylphenol Manufacturing Example 50: 2-(3,5-dimethyl-1H-pyrazole-1-yl)-5-trifluoromethylphenol Manufacturing Example 51: 2-(3,5-dimethyl-1H-pyrazole-1-yl)-6-methylphenol Manufacturing Example 52: 2-(3,5-dimethyl-1H-pyrazole-1-yl)-5-ethylphenol Manufacturing Example 53: 2-(4-fluoro-3,5-dimethyl-1H-pyrazole-1-yl)phenol Manufacturing Example 54: 5-bromo-2-(3,5-dimethyl-1H-pyrazole-1-yl)phenol Manufacturing Example 55: 5-Bromo-2-(4-chloro-3,5-dimethyl-1H-pyrazole-1-yl)phenol Manufacturing Example 56: 5-Bromo-2-(3,4,5-trimethyl-1H-pyrazole-1-yl)phenol Manufacturing Example 57: 4-(3,5-dimethyl-1H-pyrazole-1-yl)-3-hydroxyphenyl acetate Manufacturing Example 58: 4-(4-chloro-3,5-dimethyl-1H-pyrazole-1-yl)-3-hydroxyphenyl acetate Manufacturing Example 59: 3-Hydroxy-4-(3,4,5-trimethyl-1H-pyrazole-1-yl)phenyl acetate Manufacturing Example 60: 2-(3,5-dimethyl-1H-pyrazole-1-yl)-4-methoxy-5-methylphenol Manufacturing Example 61: 4-Chloro-2-(3,5-dimethyl-1H-pyrazole-1-yl)-5-methylphenol Manufacturing Example 62: 2-(3,5-dimethyl-1H-pyrazole-1-yl)-4,5-dimethylphenol Manufacturing Example 63: 4-(4-chloro-3,5-dimethyl-1H-pyrazole-1-yl)-benzene-1,3-diol

[0036] Preferably, 2-(3,5-dimethyl-1H-pyrazole-1-yl)-5-methylphenol can be mentioned.

[0037] The compound of general formula (I) contained in the nail and / or skin topical solution for the prevention or treatment of tinea infection of the present invention can also be used as a salt. Such a salt can be any pharmaceutically acceptable salt, specifically a pharmaceutically acceptable salt derived from an inorganic acid, an organic acid, or a base. "Pharmaceutically acceptable salts" are well known in the art. For example, S.M. Berge et al. describe pharmaceutically acceptable salts in detail in the Journal of Pharmaceutical Sciences, 66, p.1 onwards (1977). Examples of typical acid addition salts include, but are not limited to, inorganic acid salts such as hydrochloride, sulfate, nitrate, hydrobromide, hydroiodide, and phosphate; organic carboxylate salts such as acetate, trifluoroacetate, lactate, citrate, oxalate, succinate, glutarate, malate, tartrate, fumarate, mandelate, maleate, benzoate, nicotinate, and phthalate; organic sulfonates such as methanesulfonate, ethanesulfonate, 2-hydroxyethanesulfonate, benzenesulfonate, p-toluenesulfonate, 2-naphthalenesulfonate, and camphorsulfonate; and acidic amino acid salts such as aspartate and glutamate. Preferred acid addition salts include inorganic acids such as hydrochloric acid, hydrobromide, sulfuric acid, and phosphoric acid; and salts with organic acids such as oxalic acid, maleic acid, methanesulfonic acid, p-toluenesulfonic acid, and citric acid. More preferably, salts with hydrochloric acid, hydrobromic acid, sulfuric acid, and methanesulfonic acid are used.

[0038] Base addition salts can be produced in situ by reacting a carboxylic acid or phenolic hydroxyl group-containing portion with a suitable base during the final isolation and purification process of the compound of the present invention. Pharmaceutically acceptable salts include, but are not limited to, alkali metal salts such as lithium salts, sodium salts, and potassium salts; alkaline earth metal salts such as calcium salts and magnesium salts; aluminum salts, ammonium salts, and organic base salts such as methylamine salt, dimethylamine salt, ethylamine salt, diethylamine salt, trimethylamine salt, triethylamine salt, tetramethylammonium salt, tetraethylammonium salt, pyridine salt, picoline salt, ethanolamine salt, diethanolamine salt, triethanolamine salt, trishydroxymethylaminomethane salt, piperidine salt, piperazine salt, dicyclohexylamine salt, and N,N-dibenzylethylenediamine salt; and basic amino acid salts such as arginine salt, lysine salt, and ornithine salt. Preferably, base addition salts include addition salts with sodium, potassium, calcium, ethanolamine, and trishydroxymethylaminomethane. More preferably, addition salts with sodium, potassium, and trishydroxymethylaminomethane are used.

[0039] Furthermore, the compounds of general formula (I) contained in the nail and / or skin topical solutions for the prevention or treatment of tinea infection of the present invention may also be used in the form of solvates. As used herein, the term “solvate” means a complex of various stoichiometric values ​​formed by a solute (in the present invention, the compounds of formula (I) or salts thereof) and a solvent. Such solvents for the purposes of the present invention are preferably pharmaceutically acceptable solvents that do not interfere with the biological activity of the solute. Examples of suitable solvents for solvates include, but are not limited to, water, methanol, ethanol, ethylene glycol, propylene glycol, ethyl acetate, and butyl acetate. Preferably, the solvents for solvates are water, ethanol, and ethyl acetate.

[0040] Method for producing a compound represented by general formula (I) The 2-(1H-pyrazole-1-yl)phenol derivative represented by general formula (I) contained in the topical solution of the present invention can be synthesized by any method, but for example, it can be synthesized by the method shown in Scheme 1 or a similar method. In Scheme 1, the symbols of the compound are as described above, where P and P' represent hydrogen or a suitable protecting group, X represents a halogen or a suitable boronic acid group, and Y represents the dissociated ion of the acid used in the reaction. In this specification, "suitable boronic acid" refers to a boronic acid or a boronic acid ester.

[0041]

[0042] A method for obtaining a hydrazine derivative (V) or a salt thereof from a 2-hydroxyaniline derivative (IIIa) or a salt thereof via a diazonium compound (IVa) can be carried out in accordance with the method described in Organic Synthesis Collective Volume 1, pp. 442-445, J. Org. Chem., Vol. 21, pp. 394-399, 1956, WO2007 / 083320, US6852890.

[0043] The diazotization reaction can be carried out using nitrites such as potassium nitrite, calcium nitrite, silver nitrite, sodium nitrite, and barium nitrite, or nitrite esters such as nitrosyl sulfate, ethyl nitrite, isoamyl nitrite, isobutyl nitrite, isopropyl nitrite, tert-butyl nitrite, n-butyl nitrite, and n-propyl nitrite. Preferably, sodium nitrite or nitrite esters such as isoamyl nitrite and tert-butyl nitrite are used.

[0044] When protecting groups are used, any group that is inert in steps other than deprotection may be used, and P and P' may include, but are not limited to, alkyl groups such as methyl group, isopropyl group, allyl group, tert-butyl group, methoxymethyl group, methylthiomethyl group, benzyl group and 9-anthrylmethyl group, or acyl groups such as pivaloyl group and benzoyl group, or sulfonyl groups such as p-toluenesulfonyl group and methanesulfonyl group. Preferred protecting groups include methyl group, p-toluenesulfonyl group and methanesulfonyl group.

[0045] The amount of reagent used in the diazotization reaction is preferably 1 to 10 equivalents, and more preferably 1 to 3 equivalents, relative to the 2-hydroxyaniline derivative (IIIa).

[0046] When using a nitrite, the above diazotization reaction can use water, an organic solvent mixed with water in any proportion, such as methanol, ethanol, 2-propanol, acetic acid, trifluoroacetic acid, tetrahydrofuran, 1,4-dioxane, dimethylformamide, and dimethyl sulfoxide. Furthermore, a mixture of several of these solvents can also be used. Preferably, water, a water-methanol mixture, or a water-methanol-acetic acid mixture are used. Furthermore, in order to ensure the solubility of the aniline derivative substrate and to generate nitrite in the reaction system, the diazotization reaction is carried out under acidic conditions. Examples of acids that can be used include hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, acetic acid, trifluoroacetic acid, and phosphoric acid. Preferably, hydrochloric acid, acetic acid, and trifluoroacetic acid are used. Furthermore, these acids can also be used as solvents.

[0047] In the above diazotization reaction, when a nitrite ester is used, alcohols such as methanol, ethanol, methoxyethanol, ethoxyethanol, 1-propanol, 2-propanol, 1-butanol, 2-butanol, and 2-methyl-2-propanol, ether solvents such as diethyl ether, diisopropyl ether, tetrahydrofuran, methyl-tert-butyl ether, diphenyl ether, and 1,4-dioxane, acetate esters such as methyl acetate, ethyl acetate, propyl acetate, and butyl acetate, aprotic solvents such as N,N-dimethylformamide, N,N-dimethylacetamide, N-methylpyrrolidone, and dimethyl sulfoxide, and halogen solvents such as dichloromethane, chloroform, and 1,2-dichloroethane can be used. Furthermore, a mixture of several of these solvents can also be used. Preferably, a mixture of methanol, ethanol, and ethanol-diethyl ether is used.

[0048] The temperature for the above diazotization reaction is preferably between -50°C and 50°C, and more preferably between -30°C and 10°C, regardless of whether a nitrite or nitrite ester is used. Even more preferably, it is between -10°C and 5°C.

[0049] The above diazotization reaction can be completed in 5 minutes to 12 hours, and is usually completed within 3 hours, although this may vary depending on the substrate and reaction conditions.

[0050] The concentration of the substrate in the above diazotization reaction solution is not particularly limited, but can be in the range of 0.1 mM to 10 M. Preferably, it is in the range of 1 mM to 1 M.

[0051] For the reduction of the diazonium compound (IVa) to the hydrazine derivative (V), stannous chloride or its hydrate, sulfite, bisulfite, dithionite, or triphenylphosphine can be used (Organic Synthesis Collective Volume 1, pp. 442-445, J. Org. Chem., Vol. 21, pp. 394-399, 1956, WO2007 / 083320, US6852890, US2007 / 0105866, J. Am. Chem. Soc., Vol. 92, pp. 853-859, 1970). Preferably, a method using stannous chloride, dithionite, or sulfite is used.

[0052] The above reduction reaction can be carried out following the diazotization reaction. That is, without isolating the generally unstable diazonium compound, it is possible to synthesize the hydrazine derivative (V) or a salt thereof by adding a reducing reagent to the reaction solution, or by adding the diazotization reaction solution to a solution of the reducing reagent.

[0053] The amount of the reducing agent is preferably 1 to 30 equivalents, and more preferably 1 to 10 equivalents, relative to the corresponding diazonium compound.

[0054] The solvent used in the reduction reaction may be the same as the solvent used in the diazotization reaction, or additional solvents may be added as appropriate, but it is preferable that it be the same as the solvent used in the diazotization reaction.

[0055] The temperature of the above reduction reaction varies depending on the type of reducing agent, but is preferably between -50°C and 120°C, and more preferably between -10°C and 70°C. Even more preferably between -10°C and 30°C.

[0056] Hydrazine derivative (V) or its salt can also be synthesized from compound (IIIb) without going through diazonium compound (IVa). That is, hydrazine derivative (V) or its salt can also be obtained by reacting compound (IIIb) with hydrazine or P'-protected hydrazine, either in the presence or absence of a suitable catalyst.

[0057] Phenylpyrazole derivatives (VI) can also be synthesized by reacting compound (IIIb) with a suitable pyrazole, either in the presence or absence of a suitable catalyst.

[0058] When using hydrazine bonded with a protecting group P', any inert group other than deprotection may be used. Examples of P' include alkyloxycarbonyl groups such as methoxycarbonyl group, ethoxycarbonyl group, tert-butoxycarbonyl group, and benzyloxycarbonyl group, or acyl groups such as pivaloyl group and benzoyl group, or sulfonyl groups such as p-toluenesulfonyl group and methanesulfonyl group, but are not limited to these. A preferred protecting group is the t-butoxycarbonyl group.

[0059] When X in compound (IIIb) is a halogen, the procedure can be carried out in accordance with the method described in Organic Letters Vol.3, pp.3803-3805, 2001; J.Org.Chem., Vol.72, pp.6190-6199, 2007; and J.Org.Chem., Vol.70, pp.5164-5173, 2005. When X in compound (IIIb) is a boronic acid, the procedure can be carried out in accordance with the method described in Bioorg. Med. Chem. Lett. Vol.18, pp.4438-4441, 2008.

[0060] The amount of hydrazine or P'-protected hydrazine or pyrazole used in the above reaction is preferably 1 to 30 equivalents, and more preferably 1 to 5 equivalents, relative to compound (IIIb).

[0061] Suitable solvents for the above reaction vary depending on the substrate and reaction conditions, but examples include, but are not limited to, aprotic solvents such as N,N-dimethylformamide, N,N-dimethylacetamide, N-methylpyrrolidone, dimethyl sulfoxide, sulfolane, acetonitrile, and propionitrile; ether solvents such as 1,4-dioxane, 1,2-dimethoxyethane, and 1,2-diethoxyethane; and halogenated solvents such as chloroform, 1,2-dichloroethane, 1,1,2,2-tetrachloroethane, and 1,1,1-trichloroethane. Furthermore, a mixture of several of these solvents can also be used. If the substrate is a liquid, the reaction can be carried out without using a solvent. Preferably, N,N-dimethylformamide, N-methylpyrrolidone, propionitrile, or dimethyl sulfoxide is used, or the reaction is carried out without a solvent.

[0062] In the above reaction, in addition to salts of copper or palladium, a suitable ligand coordinated to copper or palladium can be used in catalytic or stoichiometric amounts. In this case, it is preferable to use organic bases such as 1,4-diazabicyclo[2,2,2]octane, 1,8-diazabicyclo[5,4,0]undecene, pyridine, N,N-dimethylaminopyridine, tert-butoxypotassium, tert-butoxysodium, or inorganic bases such as potassium carbonate, cesium carbonate, or potassium phosphate. More preferably, pyridine, potassium carbonate, cesium carbonate, or potassium phosphate are used.

[0063] Suitable ligands include, but are not limited to, tributylphosphine, triphenylphosphine, N-methylglycine, N,N-dimethylglycine, 1,2-diaminocyclohexane, 1,10-phenanthroline derivatives, 8-hydroxyquinoline, picolinic acid, and 2,2'-bipyridine. Preferably, N,N-dimethylglycine, 1,2-diaminocyclohexane, and 8-hydroxyquinoline are used.

[0064] Adding a small amount of water, polyethylene glycol, etc. may yield favorable results in the above reaction.

[0065] When X in compound (IIIb) is a boronic acid, favorable results can be obtained by appropriately blowing air or oxygen into the reaction system.

[0066] The temperature of the above reaction varies depending on the type of substrate and the presence and type of catalyst, but is preferably 10°C to 200°C, and more preferably 20°C to 150°C. At this time, the reaction may be accelerated by irradiation with microwaves.

[0067] The above reaction varies depending on the type of substrate and the presence and type of catalyst, but it usually takes 15 minutes to 96 hours, and is often completed within 48 hours.

[0068] The substrate concentration in the above reaction is not particularly limited, but is usually 1 mM to neat (solvent-free). Preferably it is 10 mM to 10 M.

[0069] The deprotection reaction from compound (IVb) to (V) or its salt can be carried out using an appropriate method depending on the P' used, referring to Green, Protective Groups in Organic Synthesis (5th), 1999, John Wieley & Sons. Specifically, when P' is a tert-butoxycarbonyl group, it is preferable to use an acid such as hydrochloric acid or trifluoroacetic acid. In this case, the presence of anisole or thioanisole may yield good results.

[0070] The obtained hydrazine derivative (V) or a salt thereof can be reacted with a 1,3-diketone or a chemical equivalent thereof to synthesize a phenylpyrazole derivative (VI) that forms a pyrazole ring. Here, a chemical equivalent means a compound in which the carbonyl group is protected with an acetal group, which can be easily converted to a ketone group by an acid present in the system during the pyrazole ring formation reaction.

[0071] The amount of 1,3-diketone or its chemical equivalent used in the above reaction is preferably 1 to 20 equivalents, and more preferably 1 to 5 equivalents, relative to compound (V).

[0072] Suitable solvents for the above reaction vary depending on the substrate and reaction conditions, but include methanol, ethanol, methoxyethanol, ethoxyethanol, 1-propanol, 2-propanol, 1-butanol, 2-butanol, 2-methyl-2-propanol, alcohols such as glycerol and 1,3-propanediol, diethyl ether, diisopropyl ether, tetrahydrofuran, methyl-tert-butyl ether, diphenyl ether, 1,4-dioxane, diethylene glycol dimethyl ether, 1,2-dimethoxyethanol Examples of solvents include, but are not limited to, ether-based solvents such as ethanol and 1,2-diethoxyethane; acetic acid esters such as methyl acetate, ethyl acetate, propyl acetate and butyl acetate; aprotic solvents such as N,N-dimethylformamide, N,N-dimethylacetamide, N-methylpyrrolidone, dimethyl sulfoxide, acetonitrile and propionitrile; and halogen-based solvents such as dichloromethane, chloroform, 1,2-dichloroethane, 1,1,2,2-tetrachloroethane and 1,1,1-trichloroethane. Furthermore, mixtures of these solvents can also be used. It is preferable to use methanol, ethanol, 2-propanol, 1,2-dimethoxyethane and N,N-dimethylformamide.

[0073] When the hydrazine derivative (V) is used in the above reaction as a free product, a suitable acid can be added in a catalytic amount or 1 equivalent or more.

[0074] Suitable acids include hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, acetic acid, trifluoroacetic acid, and phosphoric acid. Hydrochloric acid and trifluoroacetic acid are preferred.

[0075] The temperature of the above reaction varies depending on the type of substrate, but is preferably 10°C to 200°C, and more preferably 40°C to 120°C.

[0076] The above reaction, although it varies depending on the type of substrate, is usually completed within 12 hours, but can take anywhere from 15 minutes to 24 hours.

[0077] The substrate concentration in the above reaction is not particularly limited, but is usually 0.1 mM to 1 M. Preferably it is 10 mM to 1 M.

[0078] The obtained phenylpyrazole derivative (VI) can be converted to compound (I) of the present invention by deprotection of the protecting group if necessary. The deprotection reaction can be carried out using an appropriate method depending on the P used, with reference to Green, Protective Groups in Organic Synthesis (5th), 1999, John Wieley & Sons. When P is a methyl group, it is preferable to use boron tribromide, aluminum chloride, etc. When P is a benzyl group, catalytic hydrogenation reduction, etc. When P is a p-toluenesulfonyl group, it is preferable to use sodium hydroxide or potassium hydroxide, etc.

[0079] Compound (I) of the present invention can be further chemically modified by conventional organic chemical reactions, either by further modification of one or both of the benzene ring side chain or the pyrazole ring side chain. For example, compounds having a carboxyl group can be subjected to reactions such as esterification, amidation, and reduction to an alcohol, while compounds having an amino group can be subjected to reactions such as alkylation, acylation, and carbamate, which are easily conceivable by those skilled in the art with knowledge of organic chemistry.

[0080] The compound (I) of the present invention can also be synthesized using a 2-nitroaniline derivative (IIIc) or a nitrobenzene derivative (IIId) having a halogen or boronic acid group at the 2 position, as shown in Scheme 2. In Scheme 2, P' represents hydrogen or a suitable protecting group, X represents a halogen or a suitable boronic acid group, and Y represents the dissociated ion of the acid used in the reaction.

[0081]

[0082] The diazotization of the 2-nitroaniline derivative (IIIc), the reduction of the resulting diazonium compound, and the cyclization of the pyrazole ring can be synthesized according to the production methods (IIIa) to (V) and (V) to (VI) described above.

[0083] The reaction from nitrobenzene derivative (IIId) to 2-nitrophenylpyrazole derivative (VIII) can be synthesized according to the production methods described above for (IIIb) to (VI). Alternatively, it can be synthesized according to the method described in J. Org. Chem., vol.76, pp. 654-660, 2011.

[0084] The reduction from 2-nitrophenylpyrazole derivative (VIII) to 2-aminophenylpyrazole derivative (IX) can be carried out using catalytic hydrogenation reduction, reduction in the presence of an acid, reduction with a metal, reduction with a metal hydride, etc., as can be seen in Experimental Chemistry Course, 4th Edition, pp. 159-266.

[0085] In the case of catalytic hydrogenation reduction reactions, the hydrogenation pressure is carried out at 1 to 80 atmospheres, preferably 1 to 5 atmospheres.

[0086] Suitable solvents for the above reaction vary depending on the substrate and reaction conditions, but include, but are not limited to, methanol, ethanol, methoxyethanol, ethoxyethanol, alcohols such as 1-propanol, 2-propanol, 1-butanol, 2-butanol and 2-methyl-2-propanol, ether solvents such as diethyl ether, diisopropyl ether, tetrahydrofuran, methyl-t-butyl ether, diphenyl ether, diethylene glycol dimethyl ether and 1,4-dioxane, acetic acid esters such as methyl acetate, ethyl acetate, propyl acetate and butyl acetate, N,N-dimethylformamide, N,N-dimethylacetamide, N-methylpyrrolidone, dimethyl sulfoxide, glycerol, 1,3-propanediol, 1,2-dimethoxyethane, 1,2-diethoxyethane, water and acetic acid. Furthermore, a mixture of several of these solvents can also be used. It is preferable to use methanol, ethanol, 2-propanol and 1,2-dimethoxyethane.

[0087] The catalyst used in the catalytic hydrogenation-reduction reaction is a metal such as palladium, platinum, rhodium, or nickel, or a complex of these metals or their salts adsorbed onto activated carbon. Palladium-carbon and Raney nickel are preferred.

[0088] The temperature of the catalytic hydrogenation-reduction reaction described above varies depending on the type of substrate and catalyst, but is preferably 0°C to 100°C, and more preferably 10°C to 50°C.

[0089] The above catalytic hydrogenation-reduction reaction takes 15 minutes to 24 hours, and is usually completed within 12 hours, although this varies depending on the type of substrate.

[0090] The concentration of the substrate in the above catalytic hydrogenation-reduction reaction is not particularly limited, but is usually 0.1 mM to 1 M. Preferably it is 1 mM to 100 mM.

[0091] When using a metal as a reducing agent, the metals used may be iron, tin, zinc, etc., and it is necessary to add an acid to all of them. Hydrochloric acid, sulfuric acid, acetic acid, trifluoroacetic acid, and phosphoric acid can be used as acids, but hydrochloric acid is preferred. Furthermore, these acids can also be used in conjunction with the solvent.

[0092] The amount of metal used in the above reaction is preferably 1 to 100 equivalents, and more preferably 3 to 15 equivalents, relative to compound (VIII).

[0093] Suitable solvents for the above reaction vary depending on the substrate and reaction conditions, but include, but are not limited to, water, acetic acid, methanol, ethanol, methoxyethanol, ethoxyethanol, alcohols such as 1-propanol, 2-propanol, 1-butanol, 2-butanol and 2-methyl-2-propanol, ether solvents such as diethyl ether, diisopropyl ether, tetrahydrofuran, diphenyl ether, diethylene glycol dimethyl ether and 1,4-dioxane, acetic acid esters such as methyl acetate, ethyl acetate, propyl acetate and butyl acetate, N,N-dimethylformamide, N,N-dimethylacetamide, N-methylpyrrolidone, dimethyl sulfoxide, glycerol, 1,3-propanediol, 1,2-dimethoxyethane and 1,2-diethoxyethane. Furthermore, mixtures of these solvents can also be used. Hydrochloric acid, acetic acid, ethanol, 2-propanol and mixtures thereof are preferred.

[0094] The temperature of the above reaction varies depending on the type of substrate and conditions, but is preferably 0°C to 100°C, and more preferably 20°C to 50°C.

[0095] The above reaction, although it varies depending on the type of substrate and conditions, is usually completed within 1 to 24 hours, and typically within 12 hours.

[0096] The substrate concentration in the above reaction is not particularly limited, but is usually 0.1 mM to 1 M. Preferably it is 1 mM to 100 mM.

[0097] In the case of reduction reactions using metal hydrides, lithium borohydride, sodium borohydride, potassium borohydride, zinc borohydride, lithium triethoxyborane, and diisobutylaluminum hydride are used as reagents, but lithium borohydride or sodium borohydride is preferred. In this case, the presence of stannous chloride, nickel(II) chloride, etc. may yield good results.

[0098] The amount of reducing agent used in the above reaction is preferably 1 to 50 equivalents, and more preferably 1 to 5 equivalents, relative to compound (VIII).

[0099] Suitable solvents for the above reaction vary depending on the type of substrate and reducing agent, but include, but are not limited to, ether-based solvents such as diethyl ether, diisopropyl ether, tetrahydrofuran, diphenyl ether, 1,4-dioxane, diethylene glycol dimethyl ether, 1,2-dimethoxyethane and 1,2-diethoxyethane, and alcohols such as methanol, ethanol, methoxyethanol, ethoxyethanol, 1-propanol, 2-propanol, 1-butanol, 2-butanol and 2-methyl-2-propanol. Furthermore, a mixture of several of these solvents can also be used. Preferably, methanol and a mixture of methanol and diethylene glycol dimethyl ether are used.

[0100] The temperature of the above reaction varies depending on the type of substrate and conditions, but is preferably -80°C to 100°C, and more preferably -20°C to 80°C.

[0101] The above reaction, although it varies depending on the type of substrate and conditions, is usually completed within 12 hours, but typically takes between 15 minutes and 24 hours.

[0102] The substrate concentration in the above reaction is not particularly limited, but is usually 0.1 mM to 1 M. Preferably it is 1 mM to 100 mM.

[0103] The obtained 2-aminophenylpyrazole derivative (IX) can be diazotized according to the method for producing (IIIa) to (IVa) described above and according to Japanese Patent Application Publication No. 8-53401.

[0104] The reaction from a diazonium compound to (I) can be carried out in accordance with the methods described in Japanese Patent Publication No. 8-188545 and Japanese Patent Publication No. 11-60528.

[0105] The hydrolysis of the above diazonium salt can be carried out by heating under acidic conditions in water or a water-containing solvent.

[0106] Suitable solvents for the above reaction vary depending on the substrate and reaction conditions, but include, but are not limited to, water, acetic acid, trifluoroacetic acid, methanol, ethanol, methoxyethanol, ethoxyethanol, glycerol, alcohols such as 1,3-propanediol, 1-propanol, 2-propanol, 1-butanol, 2-butanol and 2-methyl-2-propanol, ether solvents such as tetrahydrofuran, diethylene glycol dimethyl ether, 1,2-dimethoxyethane, 1,2-diethoxyethane and 1,4-dioxane, and aprotic solvents such as N,N-dimethylformamide, N,N-dimethylacetamide, N-methylpyrrolidone and dimethyl sulfoxide. Furthermore, mixtures of multiple of these solvents can also be used. Water, sulfuric acid, hydrochloric acid, trifluoroacetic acid, acetic acid, methanol, ethanol and any mixture thereof are preferred.

[0107] The temperature of the above reaction varies depending on the type of substrate and conditions, but is preferably 20°C to 200°C, and more preferably 50°C to 150°C.

[0108] The above reaction, although it varies depending on the type of substrate and conditions, is usually completed within 12 hours, but typically takes between 10 minutes and 24 hours.

[0109] The substrate concentration in the above reaction is not particularly limited, but is usually 0.1 mM to 1 M. Preferably it is 1 mM to 100 mM.

[0110] About film-forming agents The present invention provides a topical solution for nails and / or skin for the prevention or treatment of tinea infection, comprising a compound represented by the above-described general formula (I) or a salt thereof, together with a film-forming agent. Such a film-forming agent may be any film-forming agent commonly used in topical solutions for nails or skin. Such a film-forming agent may contain a solvent and additives. Examples of additives include polymers, and examples of solvents include organic solvents. Examples of polymers include water-soluble polymers and water-insoluble polymers. Examples of water-soluble polymers include copolyvidone, povidone, hydroxypropylcellulose, hypromellose, and polyvinyl alcohol, while examples of water-insoluble polymers include acrylic resin alkanolamine, aminoalkyl methacrylate copolymer RS, aminoalkyl methacrylate copolymer E, and polyvinyl acetal diethylaminoacetate. Examples of solvents include lower alcohols, ethyl acetate, and butyl acetate, with examples of lower alcohols including methanol, ethanol, and isopropanol. Ethanol is preferred.

[0111] (1) Water-soluble polymer-containing film-forming agent Examples of water-soluble polymer-containing film-forming agents include copolyvidone (Plasdon S-630 from Ashland, or Coridone VA64 from BASF), povidone (Plasdon K-12, Plasdon K-17, Plasdon K-25, Plasdon K-29 / 32, Plasdon K-90, Plasdon K-90D from Ashland), hydroxypropylcellulose (HPC-SSL, HPC-SL, HPC-L from Nippon Soda), hypromellose (TC-5E, TC-5R, TC-5M from Shin-Etsu Chemical Co., Ltd.), and polyvinyl alcohol (Gosenol from Nippon Synthetic Chemical Co., Ltd.).

[0112] (2) Water-insoluble polymer-containing film-forming agent Examples of water-insoluble polymer-containing film-forming agents include acrylic resin alkanolamine (Plussize L-53 series, Plussize L-9000 series, manufactured by Go-o Chemical Industry Co., Ltd.), aminoalkyl methacrylate copolymer RS ​​(Eudragit RS, Eudragit RL, etc., manufactured by Evonik Corporation), aminoalkyl methacrylate copolymer E (Eudragit E, manufactured by Evonik Corporation), and polyvinyl acetal diethylaminoacetate (AEA Sankyo, manufactured by Sankyo Co., Ltd.).

[0113] The proportion of the compound of general formula (I) or its salt relative to the total amount of liquid preparation The proportion of the compound of general formula (I) or its salt in the topical solution for nails and / or skin of the present invention can be appropriately determined depending on the type of compound. When the compound of general formula (I) or its salt is formulated together with a water-soluble polymer-containing film-forming agent or a water-insoluble film-forming agent, the compound of general formula (I) or its salt is formulated in an amount of 1 to 50% by mass, more preferably 1 to 30% by mass, even more preferably 1 to 20% by mass, and particularly preferably 5 to 15% by mass, based on the total mass of the liquid. Other additives In addition to the film-forming agent, the topical solution for nails and / or skin of the present invention may contain preservatives, solvents, permeability enhancers, antioxidants, viscosity enhancers, etc., which are commonly used in topical preparations.

[0114] As preservatives, for example, organic preservatives (cationic surfactants, phenols, sorbates, salicylates, dehydroacetates and benzoates, etc.) and inorganic preservatives (antibacterial zeolites obtained by ion exchange of antibacterial metal ions such as silver, copper and zinc with zeolites, etc.) can be incorporated. Examples of solvents include polyhydric alcohols (glycerin, sorbitol, ethylene glycol, propylene glycol, dipropylene glycol, 1,3-butylene glycol, 1,3-tetramethylene glycol, polyethylene glycol, etc.), phenols (thymol, safrole, isosafrole, eugenol, isoeugenol, etc.), higher alcohols (benzyl alcohol, oleyl alcohol, cetyl alcohol, stearyl alcohol, cetostearyl alcohol, octyldodecanol, etc.), ester surfactants (sorbitan sesquioleate, polyoxyethylene hydrogenated castor oil, polyoxyl stearate, etc.), fatty acid esters (isopropyl myristate, octyldodecyl myristate, oleyl oleate, diethyl phthalate, dibutyl phthalate, etc.), (meth)acrylic acid esters (aminoalkyl methacrylate copolymer, etc.), and organic acids (lactic acid, citric acid, tartaric acid, maleic acid, malic acid, etc.).

[0115] Examples of permeation enhancers include fatty acids, fatty acid esters (isopropyl myristate, isopropyl palmitate, diisopropyl sebacate, diethyl sebacate, diisopropyl adipate, diethyl adipate, etc.), fatty acid amides, fatty alcohols, 2-(2-ethoxyethoxy)-ethanol, glycerol esters, glycerol monolaurate, propylene glycol, polyethylene glycol, unsaturated polyglycolized glycerides, saturated polyglycerides, α-hydroxy acids, dimethyl sulfoxides, decyl methyl sulfoxides, pyrrolidones, salicylic acid, lactic acid, dimethylformamide, dimethylacetamide, sodium dodecyl sulfate, phospholipids, oleic acid, oleic acid / 2-(2-ethoxyethoxy)ethanol, proteolytic enzymes, and N-acetylcysteine.

[0116] Examples of antioxidants include 1,3-butylene glycol, citric acid monohydrate, tocopherol, tocopherol acetate, ascorbic acid palmitate, butylhydroxyanisole (BHA), dibutylhydroxytoluene (BHT), and propyl gallate. Examples of viscosity enhancers that improve tactile feel include silicone derivatives (cyclic silicones, dimethylpolysiloxane, etc.), hydrophobized hydroxypropyl methylcellulose, and poloxamer. Therefore, in one embodiment, the topical solution for nails and / or skin of the present invention comprises a viscosity enhancer, preferably a silicone derivative, hydrophobized hydroxypropyl methylcellulose, or poloxamer.

[0117] Method for producing the topical liquid preparation of the present invention To produce the topical solution of the present invention, the active ingredient, a compound of general formula (I) or its salt, and a film-forming agent, etc., were sequentially dissolved in a portion of the solvent, and the amount was adjusted with the solvent to obtain the formulation. Alternatively, the usual method for producing topical solutions can be used to produce the topical solution of the present invention. The present invention will be described below with reference to examples, but the present invention is not limited to these examples. In the examples, "%" means "mass percent". Also, "room temperature" in the examples usually refers to a temperature of about 1°C to about 40°C.

[0118] 1. Preparation of compounds of general formula (I) Manufacturing Example 1: 2-(3,5-dimethyl-1H-pyrazole-1-yl)phenol a) 1-(2-methoxyphenyl)-3,5-dimethyl-1H-pyrazole 3.50 g of 2-methoxyphenylhydrazine hydrochloride was dissolved in 60 ml of ethanol, and 2.06 ml of acetylacetone was added and the mixture was heated under reflux for 1 hour. 150 ml of water was added to the reaction mixture, neutralized with saturated sodium carbonate aqueous solution, and extracted with 150 ml of ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate, the solvent was removed under reduced pressure, and the mixture was purified by silica gel column chromatography (hexane:ethyl acetate = 2:1) to obtain 3.88 g of the title compound. 1 H-NMR(CDCl3);δ(ppm) 2.08(3H, s), 2.29(3H, s), 3.78(3H, s), 5.95(1H, s), 6.98-7.03(2H, m), 7.29-7.32(1H, m), 7.34-7.39(1H, m). MS(ESI); m / z 203(M+H) +

[0119] b) 2-(3,5-dimethyl-1H-pyrazole-1-yl)phenol 3.88 g of 1-(2-methoxyphenyl)-3,5-dimethyl-1H-pyrazole was dissolved in 40 ml of methylene chloride, and 32 ml of 1 M methylene chloride solution of boron tribromide was added. The mixture was stirred at room temperature for 1.5 hours. The reaction mixture was added to 150 ml of water, neutralized with 1N sodium hydroxide, and extracted with 150 ml of ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate, the solvent was removed under reduced pressure, and the mixture was purified by silica gel column chromatography (hexane:ethyl acetate = 3:1) to obtain 2.83 g of the title compound. 1 H-NMR(CDCl3);δ(ppm) 2.29(3H,s), 2.38(3H, s), 6.02(1H, s), 6.87-6.6.91(1H, m), 7.06-7.09(1H, m), 7.16-7.20(1H, m). MS(ESI); m / z 189(M+H) +

[0120] Production Example 2 2-(3,5-dimethyl-1H-pyrazole-1-yl)-4-fluorophenol a) 2-amino-4-fluorophenol 300 mg of 4-fluoro-2-nitrophenol was dissolved in 3 ml of ethanol, 120 mg of 10% palladium / carbon was added, and the mixture was stirred at room temperature under a hydrogen atmosphere for 1 hour. After filtering out the insoluble matter, the filtrate was removed under reduced pressure to obtain 211 mg of the title compound. 1 H-NMR(DMSO-d6);δ(ppm) 4.80(2H, s), 6.09-6.14(1H, m), 6.34-6.37(1H, m), 6.53-6.57(1H, m), 8.93(1H, s). MS(FAB); m / z 128(M+H) +

[0121] b) 2-(3,5-dimethyl-1H-pyrazole-1-yl)-4-fluorophenol 100 mg of 2-amino-4-fluorophenol was added to 0.8 ml of 5N hydrochloric acid, and a solution of 65 mg of sodium nitrite dissolved in 0.2 ml of water was added dropwise at 0°C, and the mixture was stirred for 30 minutes. Next, a solution of 249 mg of stannous chloride dissolved in 0.46 ml of 5N hydrochloric acid was added dropwise at 0°C, and the mixture was stirred at 0°C for 30 minutes, then at room temperature for 2 hours. The solvent was removed under reduced pressure, and 2.5 ml of ethanol and 81 μl of acetylacetone were added, and the mixture was heated under reflux for 4 hours. 50 ml of water was added to the reaction mixture, neutralized with saturated sodium bicarbonate solution, and extracted with 50 ml of ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate, and the solvent was removed under reduced pressure. The mixture was purified by silica gel column chromatography (hexane:ethyl acetate = 2:1) to obtain 20.6 mg of the title compound. 1 H-NMR(CDCl3);δ(ppm) 2.24(3H, s), 2.33(3H, s), 5.99(1H, s), 6.82-6.90(2H, m), 6.95-6.98(1H, m). MS(FAB); m / z 207(M+H) +

[0122] Production Example 3 2-(1H-pyrazole-1-yl)phenol a) 1-(2-methoxyphenyl)-1H-pyrazole 200 mg of 2-methoxyphenylhydrazine hydrochloride was dissolved in 5 ml of ethanol, and 189 μl of malonaldehyde (bisdimethylacetal) was added and the mixture was heated under reflux for 2 hours. 50 ml of water was added to the reaction mixture, neutralized with saturated sodium carbonate aqueous solution, and extracted with 60 ml of ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate, and the solvent was removed under reduced pressure to obtain 179.4 mg of the title compound. 1 H-NMR(CDCl3);δ(ppm) 3.87(3H,s), 6.42(1H, d, J=2.4Hz), 7.02-7.07(2H, m), 7.27-7.32(1H, m), 7.68-7.72(2H, m), 8.01(1H, d, J=2.4Hz). MS(FAB); m / z 175(M+H) +

[0123] b) 2-(1H-pyrazole-1-yl)phenol 121 mg of the title compound was obtained from 178 mg of 1-(2-methoxyphenyl)-1H-pyrazole by the same method as in Preparation Example 1b). 1 H-NMR(CDCl3);δ(ppm) 6.49(1H, d, J=2.4Hz), 6.88-6.92(1H, m), 7.08-7.10(1H, m), 7.14-7.18(1H, m), 7.35-7.37(1H, m), 7.72(1H, s), 7.99(1H, d, J=2.4Hz). MS(ESI); m / z 161(M+H) +

[0124] Production Example 4 2-(5-hydroxy-3-methyl-1H-pyrazole-1-yl)phenol a) 5-hydroxy-1-(2-methoxyphenyl)-3-methyl-1H-pyrazole 55.1 mg of the title compound was obtained from 150 mg of 2-methoxyphenylhydrazine hydrochloride and 93 μl of methyl acetoacetate by the same method as in Preparation Example 1a). 1 H-NMR(CDCl3);δ(ppm) 2.11(3H, s), 3.76(3H, s), 6.88-6.94(3H, m), 7.19-7.34(2H, m). MS(ESI); m / z 204(M+H) +

[0125] b) 2-(5-hydroxy-3-methyl-1H-pyrazole-1-yl)phenol 32.4 mg of the title compound was obtained from 52 mg of 5-hydroxy-1-(2-methoxyphenyl)-3-methyl-1H-pyrazole by the same method as in Preparation Example 1b). 1 H-NMR(CDCl3);δ(ppm) 2.17(3H, s), 5.30(1H, s), 6.88-6.95(2H, m), 7.15(1H, t, J=7.6Hz), 7.37(1H, d, J=7.6Hz). MS(FAB); m / z 191(M+H) +

[0126] Manufacturing Example 5 2-(5-methyl-3-trifluoromethyl-1H-pyrazole-1-yl)phenol a) 1-(2-methoxyphenyl)-5-methyl-3-trifluoromethyl-1H-pyrazole 300 mg of 2-methoxyphenylhydrazine hydrochloride was dissolved in 1.3 ml of 2-methoxyethanol, and 2.5 ml of acetic acid and 208 μl of 1,1,1-trifluoro-2,4-pentanedione were added. The mixture was heated under reflux for 1 hour and 40 minutes. The solvent was removed under reduced pressure, 50 ml of ethyl acetate was added, and the organic layer, washed with 50 ml of saturated sodium bicarbonate solution and 50 ml of saturated saline solution, was dried over anhydrous magnesium sulfate, and the solvent was removed under reduced pressure to obtain 485.6 mg of the title compound. 1 H-NMR(CDCl3);δ(ppm) 2.14(3H, s), 3.78(3H, s), 6.40(1H, s), 7.00-7.07(2H, m), 7.31-7.33(1H, m), 7.41-7.45(1H, m). MS(ESI); m / z 257(M+H) +

[0127] b) 2-(5-methyl-3-(trifluoromethyl)-1H-pyrazole-1-yl)phenol 320.1 mg of the title compound was obtained from 1-(2-methoxyphenyl)-5-methyl-3-(trifluoromethyl)-1H-pyrazole by the same method as in Preparation Example 1b). 1 H-NMR(CDCl3);δ(ppm) 2.41(3H, s), 6.52(1H, s), 6.95-6.99(1H, m), 7.11-7.13(1H, m), 7.20-7.24(1H, m), 7.28-7.32(1H, m). MS(FAB); m / z 243(M+H) +

[0128] Production Example 6 2-(3,5-bistrifluoromethyl-1H-pyrazole-1-yl)phenol a) 1-(2-methoxyphenyl)-3,5-bistrifluoromethyl-1H-pyrazole The title compound was obtained from 300 mg of 2-methoxyphenylhydrazine hydrochloride and 243 μl of hexafluoroacetylacetone by the same method as in Preparation Example 5a). 1 H-NMR(CDCl3);δ(ppm) 3.77(3H, s), 7.01-7.06(3H, m), 7.33(1H, d, J=7.6Hz), 7.49(1H, d, J=7.6Hz). MS(ESI); m / z 311(M+H) +

[0129] b) 2-(3,5-bistrifluoromethyl)-1H-pyrazole-1-yl)phenol From the 1-(2-methoxyphenyl)-3,5-bistrifluoromethyl)-1H-pyrazole obtained in a) above, 455.6 mg of the title compound was obtained by the same method as in Production Example 1b). 1 H-NMR(CDCl3);δ(ppm) 6.99-7.04(1H, m), 7.07-7.08(1H, m), 7.10(1H, s), 7.32-7.41(2H, m). MS(FAB); m / z 297(M+H) +

[0130] Manufacturing Example 7 2-(3-methyl-1H-pyrazole-1-yl)phenol a) 1-(2-methoxyphenyl)-3-methyl-1H-pyrazole 115.1 mg of the title compound was obtained from 200 mg of 2-methoxyphenylhydrazine hydrochloride and 151 μl of 4,4-dimethoxybutan-2-one by the same method as in Preparation Example 1a). 1 H-NMR(CDCl3);δ(ppm) 2.31(3H, s), 3.80(3H, s), 6.14(1H, d, J=2.4Hz), 6.95-6.99(2H, m), 7.18-7.22(1H, m), 7.61-7.63(1H, m), 7.84(1H, d, J=2.4Hz). MS(FAB); m / z 189(M+H) +

[0131] b) 2-(3-methyl-1H-pyrazole-1-yl)phenol 76 mg of the title compound was obtained from 115 mg of 1-(2-methoxyphenyl)-3-methyl-1H-pyrazole by the same method as in Preparation Example 1b). 1 H-NMR(CDCl3);δ(ppm) 2.36(3H, s), 6.24(1H, d, J=2.4Hz), 6.85-6.89(1H, m), 7.05-7.14(2H, m), 7.29-7.31(1H, m), 7.86(1H, d, J=2.4Hz). MS(FAB); m / z 175(M+H) +

[0132] Production Example 8 2-(5-methyl-1H-pyrazole-1-yl)phenol a) 1-(2-methoxyphenyl)-5-methyl-1H-pyrazole 70 mg of the title compound was obtained from 200 mg of 2-methoxyphenylhydrazine hydrochloride and 151 μl of 4,4-dimethoxybutan-2-one using the same method as in Preparation Example 1a). 1 H-NMR(CDCl3);δ(ppm) 2.07(3H, s), 3.71(3H, s), 6.09(1H, s), 6.94-6.99(2H, m), 7.24-7.26(1H, m), 7.31-7.35(1H, m), 7.52(1H, s). MS(FAB); m / z 189(M+H) +

[0133] b) 2-(5-methyl-1H-pyrazole-1-yl)phenol 45.5 mg of the title compound was obtained from 69 mg of 1-(2-methoxyphenyl)-5-methyl-1H-pyrazole by the same method as in Preparation Example 1b). 1 H-NMR(CDCl3);δ(ppm) 2.41(3H, s), 6.27(1H, d, J=1.6Hz), 6.90-6.94(1H, m), 7.10-7.12(1H, m), 7.19-7.24(2H, m), 7.66(1H, d, J=1.6Hz). MS(FAB); m / z 175(M+H) +

[0134] Production Example 9 2-(3,4,5-trimethyl-1H-pyrazole-1-yl)phenol a) 1-(2-methoxyphenyl)-3,4,5-trimethyl-1H-pyrazole 200 mg of 2-methoxyphenylhydrazine hydrochloride was dissolved in 4 ml of ethanol, and 134 μl of 3-methyl-2,4-pentanedione was added and the mixture was heated under reflux for 3 hours. 50 ml of water was added to the reaction mixture, neutralized with saturated sodium carbonate aqueous solution, and extracted with 60 ml of ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate, and the solvent was removed under reduced pressure to obtain 209.8 mg of the title compound. 1 H-NMR(CDCl3);δ(ppm) 1.98(3H, s), 2.02(3H, s), 2.24(3H, s), 3.80(3H, s), 6.99-7.04(2H, m), 7.29-7.31(1H, m), 7.34-7.39(1H, m). MS(FAB); m / z 217(M+H) +

[0135] b) 2-(3,4,5-trimethyl-1H-pyrazole-1-yl)phenol 104 mg of the title compound was obtained from 209 mg of 1-(2-methoxyphenyl)-3,4,5-trimethyl-1H-pyrazole by the same method as in Preparation Example 1b). 1 H-NMR(CDCl3);δ(ppm) 1.99(3H, s), 2.25(3H, s), 2.31(3H, s), 6.90(1H, t, J=8.0Hz), 7.08(1H, d, J=8.0Hz), 7.06-7.20(2H, m), 9.89(1H, s). MS(ESI); m / z 203(M+H) +

[0136] Manufacturing Example 10 2-(5-amino-3-tert-butyl-1H-pyrazole-1-yl)phenol a) 3-tert-butyl-1-(2-methoxyphenyl)-1H-pyrazole-5-amine 310.3 mg of the title compound was obtained from 300 mg of 2-methoxyphenylhydrazine hydrochloride, 215 mg of 4,4-dimethyl-3-oxopentannitrile, and 40 μl of acetic acid by the same method as in Preparation Example 1a). 1 H-NMR(CDCl3);δ(ppm) 1.32(9H, s), 3.80(2H, s), 3.86(3H, s), 5.51(1H, s), 7.01-7.08(2H, m), 7.30-7.35(1H, m), 7.45-7.47(1H, m). MS(FAB); m / z 246(M+H) +

[0137] b) 2-(5-amino-3-tert-butyl-1H-pyrazole-1-yl)phenol 66.2 mg of the title compound was obtained from 100 mg of 3-tert-butyl-1-(2-methoxyphenyl)-1H-pyrazole-5-amine by the same method as in Preparation Example 1b). 1 H-NMR(CDCl3);δ(ppm) 1.30(9H, s), 3.93(2H, s), 5.55(1H, s), 6.90(1H, dt, J=1.6, 8.0Hz), 7.08(1H, dd, J=1.6, 8.0Hz), 7.17(1H, dt, J=1.6, 8.0Hz), 7.47(1H, dd, J=1.6, 8.0Hz), 10.39(1H, brs). MS(FAB); m / z 232(M+H) +

[0138] Production Example 11 4-Chloro-2-(3,5-dimethyl-1H-pyrazole-1-yl)phenol a) 1-(5-chloro-2-methoxyphenyl)-3,5-dimethyl-1H-pyrazole 104.8 mg of the title compound was obtained from 388 mg of 5-chloro-2-methoxyaniline hydrochloride by the same method as in Production Example 2b). 1H-NMR(CDCl3);δ(ppm) 2.11(3H, s), 2.29(3H, s), 3.79(3H, s), 5.96(1H, s), 6.93(1H, dd, J=2.4, 7.2Hz), 7.33-7.35(2H, m). MS(FAB); m / z 237(M+H) +

[0139] b) 4-Chloro-2-(3,5-dimethyl-1H-pyrazole-1-yl)phenol 67.3 mg of the title compound was obtained from 104.8 mg of 1-(5-chloro-2-methoxyphenyl)-3,5-dimethyl-1H-pyrazole by the same method as in Preparation Example 1b). 1 H-NMR(CDCl3);δ(ppm) 2.30(3H, s), 2.43(3H, s), 6.05(1H, s), 7.02(1H, d, J=8.8Hz), 7.14-7.20(2H, m), 10.08(1H, s). MS(FAB); m / z 223(M+H) +

[0140] Production Example 12 2-Chloro-6-(3,5-dimethyl-1H-pyrazole-1-yl)phenol a) 1-(3-chloro-2-methoxyphenyl)-3,5-dimethyl-1H-pyrazole 30.6 mg of the title compound was obtained from 158 mg of 3-chloro-o-anisidine using the same method as in Preparation Example 2b). 1 H-NMR(CDCl3);δ(ppm) 2.14(3H, s), 2.29(3H, s), 3.49(3H, s), 5.99(1H,s), 7.12(1H, t, J=8.0Hz), 7.27-7.31(1H, m), 7.43-7.46(1H, m). MS(ESI); m / z 236(M+H) +

[0141] b) 2-chloro-6-(3,5-dimethyl-1H-pyrazole-1-yl)phenol 27.4 mg of the title compound was obtained from 63.4 mg of 1-(3-chloro-2-methoxyphenyl)-3,5-dimethyl-1H-pyrazole by the same method as in Preparation Example 1b). 1 H-NMR(CDCl3);δ(ppm) 2.30(3H, s), 2.40(3H, s), 6.05(1H, s), 6.86(1H, t, J=8.0Hz),7.13-7.15(1H, m), 7.26-7.31(1H, m), 10.66(1H, s). MS(FAB); m / z 223(M+H) +

[0142] Production Example 13 2-(4-chloro-3,5-dimethyl-1H-pyrazole-1-yl)phenol a) 4-chloro-1-(2-methoxyphenyl)-3,5-dimethyl-1H-pyrazole 193.9 mg of the title compound was obtained from 174.6 mg of 2-methoxyphenylhydrazine hydrochloride and 114 μl of 3-chloropentane-2,4-dione by the same method as in Preparation Example 1a). 1 H-NMR(CDCl3);δ(ppm) 2.09(3H,s), 2.29(3H, s), 3.81(3H, s), 7.00-7.06(2H, m), 7.30(1H, dd, J=1.6, 7.6Hz), 7.38-7.43(1H, m). MS(FAB); m / z 237(M+H) +

[0143] b) 2-(4-chloro-3,5-dimethyl-1H-pyrazole-1-yl)phenol 151.9 mg of the title compound was obtained from 193 mg of 4-chloro-1-(2-methoxyphenyl)-3,5-dimethyl-1H-pyrazole by the same method as in Preparation Example 1b). 1H-NMR(CDCl3);δ(ppm) 2.30(3H, s), 2.37(3H, s), 6.91-6.95(1H, m), 7.09(1H, dd, J=1.6, 8.0Hz), 7.17(1H, dd, J=1.6, 8.0Hz), 7.21-7.25(1H, m), 9.23(1H, s). MS(FAB); m / z 223(M+H) +

[0144] Production Example 14 2-(3,5-diethyl-1H-pyrazole-1-yl)phenol a) 3,5-diethyl-1-(2-methoxyphenyl)-1H-pyrazole 209.8 mg of the title compound was obtained from 174.6 mg of 2-methoxyphenylhydrazine hydrochloride and 135.5 μl of 3,5-heptanedione by the same method as in Preparation Example 1a). 1 H-NMR(CDCl3);δ(ppm) 1.14-1.18(3H, m), 1.25-1.31(3H, m), 2.42(2H, q, J=7.2Hz), 2.67-2.73(2H, m), 3.78(3H, s), 6.03(1H, s), 6.99-7.04(2H, m), 7.31-7.40(2H, m). MS(FAB); m / z 231(M+H) +

[0145] b) 2-(3,5-diethyl-1H-pyrazole-1-yl)phenol 159.2 mg of the title compound was obtained from 207 mg of 3,5-diethyl-1-(2-methoxyphenyl)-1H-pyrazole by the same method as in Preparation Example 1b). 1 H-NMR(CDCl3);δ(ppm) 1.24-1.31(6H, m), 2.69(2H, q, J=7.6Hz), 2.76(2H, q, J=7.6Hz), 6.11(1H, s), 6.90(1H, q, J=7.6Hz), 7.09(1H, d, J=7.6Hz), 7.19-7.22(2H, m), 9.69(1H, s). MS(FAB); m / z 217(M+H) +

[0146] Manufacturing Example 15 3-(3,5-dimethyl-1H-pyrazole-1-yl)benzene-1,2-diol a) 1-(2,3-dimethoxyphenyl)-3,5-dimethyl-1H-pyrazole 189 mg of the title compound was obtained from 306 mg of 2,3-dimethoxyaniline using the same method as in Preparation Example 2b). 1 H-NMR(CDCl3);δ(ppm) 2.14(3H, s), 2.29(3H, s), 3.53(3H, s), 3.91(3H, s), 5.96(1H, s), 6.96-6.70(2H, m), 7.12(1H, t, J=8.0Hz). MS(FAB); m / z 233(M+H) +

[0147] b) 3-(3,5-dimethyl-1H-pyrazole-1-yl)benzene-1,2-diol 28.9 mg of the title compound was obtained from 186 mg of 1-(2,3-dimethoxyphenyl)-3,5-dimethyl-1H-pyrazole by the same method as in Preparation Example 1b). 1 H-NMR(CDCl3);δ(ppm) 2.26(3H, s), 2.38(3H, s), 5.99(1H, s), 6.75-6.85(3H, m). MS(FAB); m / z 205(M+H) +

[0148] Production Example 16 2-(3,5-dimethyl-1H-pyrazole-1-yl)benzene-1,4-diol a) 1-(2,5-dimethoxyphenyl)-3,5-dimethyl-1H-pyrazole 260.3 mg of the title compound was obtained from 306 mg of 2,5-dimethoxyaniline by the same method as in Preparation Example 2b). 1 H-NMR(CDCl3);δ(ppm) 2.11(3H, s), 2.30(3H, s), 3.73(3H, s), 3.78(3H, s), 5.96(1H, s), 6.91-6.93(3H, m).

[0149] b) 2-(3,5-dimethyl-1H-pyrazole-1-yl)benzene-1,4-diol 162.6 mg of the title compound was obtained from 260.3 mg of 1-(2,5-dimethoxyphenyl)-3,5-dimethyl-1H-pyrazole by the same method as in Preparation Example 1b). 1 H-NMR(DMSO-d6);δ(ppm) 2.07(3H, s), 2.14(3H, s), 5.93(1H, s), 6.56(1H, d, J=2.8Hz), 6.66-6.69(1H, m), 6.80(1H, d, J=8.8Hz), 9.02(1H, s), 9.17(1H, s). MS(FAB); m / z 205(M+H) +

[0150] Production Example 17 2-(4-ethyl-3,5-dimethyl-1H-pyrazole-1-yl)phenol a) 4-ethyl-1-(2-methoxyphenyl)-3,5-dimethyl-1H-pyrazole 236.6 mg of the title compound was obtained from 200 mg of 2-methoxyphenylhydrazine hydrochloride and 155 μl of 3-ethyl-2,4-pentanedione by the same method as in Preparation Example 1a). 1 H-NMR(CDCl3);δ(ppm) 1.13(3H, t, J=7.6Hz), 2.03(3H, s), 2.27(3H, s), 2.42(2H, q, J=7.6Hz), 3.79(3H, s), 6.99-7.04(2H, m), 7.30-7.39(2H, m). MS(FAB); m / z 231(M+H) +

[0151] b) 2-(4-ethyl-3,5-dimethyl-1H-pyrazole-1-yl)phenol 196.2 mg of the title compound was obtained from 232 mg of 4-ethyl-1-(2-methoxyphenyl)-3,5-dimethyl-1H-pyrazole by the same method as in Preparation Example 1b). 1H-NMR(CDCl3);δ(ppm) 1.12(3H, t, J=7.6Hz), 2.27(3H, s), 2.33(3H, s), 2.43(2H, q, J=7.6Hz), 6.88-6.92(1H, m), 7.08-7.10(1H, m), 7.06-7.19(2H, m), 9.90(1H, s). MS(FAB); m / z 217(M+H) +

[0152] Production Example 18 5-Fluoro-2-(3,4,5-trimethyl-1H-pyrazole-1-yl)phenol 114.7 mg of the title compound was obtained from 201.2 mg of 2-amino-5-fluorophenol and 184 μl of 3-methyl-2,4-pentanedione by the same method as in Preparation Example 1b). 1 H-NMR(CDCl3);δ(ppm) 1.99(3H, s), 2.23(3H, s), 2.28(3H, s), 6.59-6.64(1H, m), 6.78-6.81(1H, m), 7.10-7.14(1H, m). MS(ESI); m / z 221(M+H) +

[0153] Manufacturing Example 19 2-(4-chloro-3,5-dimethyl-1H-pyrazole-1-yl)benzene-1,4-diol a) 4-Chloro-1-(2,5-dimethoxyphenyl)-3,5-dimethyl-1H-pyrazole 333.7 mg of the title compound was obtained from 306 mg of 2,5-dimethoxyaniline and 228 μl of 3-chloropentane-2,4-dione by the same method as in Preparation Example 2b). 1 H-NMR(CDCl3);δ(ppm) 2.10(3H, s), 2.29(3H, s), 3.74(3H, s), 3.78(3H, s), 6.94-6.97(2H, m), 7.26(1H, s). MS(FAB); m / z 267(M+H) +

[0154] b) 2-(4-chloro-3,5-dimethyl-1H-pyrazole-1-yl)benzene-1,4-diol 184.8 mg of the title compound was obtained from 329 mg of 4-chloro-1-(2,5-dimethoxyphenyl)-3,5-dimethyl-1H-pyrazole by the same method as in Preparation Example 1b). 1 H-NMR(DMSO-d6);δ(ppm) 2.05(3H, s), 2.15(3H, s), 6.58(1H, d, J=2.8Hz), 6.72(1H, dd, J=2.8, 8.8Hz), 6.82(1H, d, J=8.8Hz), 9.11(1H, s), 9.33(1H, s). MS(FAB); m / z 239(M+H) +

[0155] Production Example 20 4-Fluoro-2-(3,4,5-trimethyl-1H-pyrazole-1-yl)phenol 84.8 mg of the title compound was obtained from 111 mg of 2-amino-4-fluorophenol and 102 μl of 3-methyl-2,4-pentanedione by the same method as in Preparation Example 2b). 1 H-NMR(CDCl3);δ(ppm) 1.99(3H, s), 2.23(3H, s), 2.24(3H, s), 2.34(3H, s), 6.87-6.95(2H, m), 7.00-7.03(1H, m), 9.90(1H, s). MS(FAB); m / z 221(M+H) +

[0156] Production Example 21 2-(4-chloro-3,5-dimethyl-1H-pyrazole-1-yl)-5-fluorophenol 62 mg of the title compound was obtained from 100 mg of 2-amino-5-fluorophenol and 90 μl of 3-chloropentan-2,4-dione using the same method as in Preparation Example 2b). 1H-NMR(CDCl3);δ(ppm) 2.29(3H, s), 2.35(3H, s), 6.62-6.67(1H, m), 6.78-6.81(1H, m), 7.10-7.14(1H, m), 9.44(1H, s). MS(FAB); m / z 241(M+H) +

[0157] Production Example 22 1-(2-hydroxyphenyl)-3,5-dimethyl-1H-pyrazole-4-carboxylate ethyl a) 1-(2-methoxyphenyl)-3,5-dimethyl-1H-pyrazole-4-carboxylate ethyl carboxylate 82.6 mg of the title compound was obtained from 175 mg of 2-methoxyphenylhydrazine hydrochloride and 156 μl of ethyl 2-acetyl-3-oxobutanoate by the same method as in Preparation Example 1a). 1 H-NMR(CDCl3);δ(ppm) 1.38(3H, t, J=7.6Hz), 2.33(3H, s), 2.50(3H, s), .80(3H, s), 4.32(2H, q, J=7.6Hz), 7.02-7.08(2H, m), 7.30-7.32(1H, m), 7.41-7.45(1H, m). MS(ESI); m / z 275(M+H) +

[0158] b) 1-(2-hydroxyphenyl)-3,5-dimethyl-1H-pyrazole-4-carboxylate ethyl 21 mg of the title compound was obtained from 82 mg of ethyl 1-(2-methoxyphenyl)-3,5-dimethyl-1H-pyrazole-4-carboxylate by the same method as in Preparation Example 1b). 1 H-NMR(CDCl3);δ(ppm) 1.39(3H, t, J=7.2Hz), 2.50(3H, s), 2.61(3H, s), 4.34(2H, q, J=7.2Hz), 6.96(1H, t, J=8.4Hz), 7.10(1H, d, J=8.4Hz), 7.17(1H, d, J=8.4Hz), 7.26-7.30(1H, m), 8.76(1H, s). MS(FAB); m / z 261(M+H) +

[0159] Production Example 23 3-(1-(2-hydroxyphenyl)-3,5-dimethyl-1H-pyrazole-4-yl)methyl propanoate a) Methyl 3-(1-(2-methoxyphenyl)-3,5-dimethyl-1H-pyrazole-4-yl)propanoate 96 mg of the title compound was obtained from 174.6 mg of 2-methoxyphenylhydrazine hydrochloride and 175 μl of methyl 4-acetyl-5-oxohexanoate by the same method as in Preparation Example 1a). 1 H-NMR(CDCl3);δ(ppm) 2.04(3H, s), 2.27(3H, s), 2.49-2.54(2H, m), 2.74-2.78(2H, m), 3.68(3H, s), 3.79(3H, s), 6.99-7.02(2H, m), 7.28-7.31(1H, m), 7.35-7.39(1H, m). MS(FAB); m / z 289(M+H) +

[0160] b) 3-(1-(2-hydroxyphenyl)-3,5-dimethyl-1H-pyrazole-4-yl)methyl propanoate 36.8 mg of the title compound was obtained from 96 mg of methyl 3-(1-(2-methoxyphenyl)-3,5-dimethyl-1H-pyrazole-4-yl)propanoate by the same method as in Preparation Example 1b). 1 H-NMR(CDCl3);δ(ppm) 2.28(3H, s), 2.34(3H, s), 2.51(2H, t, J=8.0Hz), 2.77(2H, t, J=8.0Hz), 3.69(3H, s), 6.91(1H, t, J=6.8Hz), 7.08-7.10(1H, m), 7.17-7.26(2H, m), 9.73(1H, s). MS(ESI); m / z 275(M+H) +

[0161] Manufacturing Example 24 2-(4-butyl-3,5-dimethyl-1H-pyrazole-1-yl)phenol a) 4-butyl-1-(2-methoxyphenyl)-3,5-dimethyl-1H-pyrazole 273 mg of the title compound was obtained from 175 mg of 2-methoxyphenylhydrazine hydrochloride and 168 μl of 3-n-butyl 2,4-pentanedione by the same method as in Preparation Example 1a). 1 H-NMR(CDCl3);δ(ppm) 0.94(3H, t, J=7.2Hz), 1.32-1.39(2H, m), 1.45-1.50(2H, m), 2.01(3H, m), 2.26(3H, s), 2.39(2H, q, J=7.2Hz), 3.79(3H, s), 6.99-7.04(2H, m), 7.30-7.38(2H, m). MS(FAB); m / z 259(M+H) +

[0162] b) 2-(4-butyl-3,5-dimethyl-1H-pyrazole-1-yl)phenol 208.8 mg of the title compound was obtained from 273 mg of 4-butyl-1-(2-methoxyphenyl)-3,5-dimethyl-1H-pyrazole by the same method as in Preparation Example 1b). 1 H-NMR(CDCl3);δ(ppm) 0.95(3H, t, J=7.6Hz), 1.33-1.39(2H, m), 1.43-1.48(2H, m), 2.26(3H, s), 2.32(3H, s), 2.40(2H, t, J=7.6Hz), 6.88-6.92(1H, m), 7.08(1H, d, J=8.4Hz), 7.16-7.20(2H, m), 9.93(1H, s). MS(FAB); m / z 245(M+H) +

[0163] Production Example 25 2-(3,5-dimethyl-1H-pyrazole-1-yl)-5-fluorophenol a) 2-amino-5-fluorophenol From 314 mg of 5-fluoro-2-nitrophenol, 252.5 mg of the title compound was obtained by the same method as in Preparation Example 2a). 1H-NMR(DMSO-d6);δ(ppm) 6.33-6.38(1H, m), 6.45-6.48(1H, m), 6.51-6.55(1H, m). MS(FAB); m / z 128(M+H) +

[0164] b) 2-(3,5-dimethyl-1H-pyrazole-1-yl)-5-fluorophenol 89.6 mg of the title compound was obtained from 150 mg of 2-amino-5-fluorophenol by the same method as in Production Example 2b). 1 H-NMR(CDCl3);δ(ppm) 2.29(3H, s), 2.37(3H, s), 6.03(1H, s), 6.60-6.65(1H, m), 6.78-6.81(1H, m), 7.13-7.16(1H, m). MS(ESI); m / z 207(M+H) +

[0165] Production Example 26 5-Chloro-2-(3,5-dimethyl-1H-pyrazole-1-yl)phenol 168.8 mg of the title compound was obtained from 287 mg of 2-amino-5-chlorophenol by the same method as in Production Example 2b). 1 H-NMR(CDCl3);δ(ppm) 2.30(3H, s), 2.40(3H, s), 6.05(1H, s), 6.87-6.90(1H, m), 7.10-7.14(2H, m), 10.23(1H, s). MS(FAB); m / z 223(M+H) +

[0166] Production Example 27 2-(3,5-dimethyl-1H-pyrazole-1-yl)-3-nitrophenol 75.4 mg of the title compound was obtained from 308 mg of 2-amino-3-nitrophenol using the same method as in Preparation Example 2b). 1H-NMR(CD3OD);δ(ppm) 2.14(3H, s), 2.19(3H, s), 6.04(1H, s), 7.27(1H, dd, J=1.6, 7.6Hz), 7.44(1H, dd, J=1.6, 7.6Hz), 7.50(1H, t, J=7.6Hz). MS(FAB); m / z 234(M+H) +

[0167] Manufacturing Example 28 2-(3,5-dimethyl-1H-pyrazole-1-yl)-5-nitrophenol 101 mg of the title compound was obtained from 308 mg of 2-amino-5-nitrophenol using the same method as in Production Example 2b). 1 H-NMR(CDCl3);δ(ppm) 2.33(3H, s), 2.50(3H, s), 6.13(1H, s), 7.38(1H, d, J=7.6Hz), 7.79-7.81(1H, m), 7.95(1H, s). MS(ESI); m / z 234(M+H) +

[0168] Manufacturing Example 29 3-(1-(2-hydroxyphenyl)-3,5-dimethyl-1H-pyrazole-4-yl)propionic acid 29.9 mg of methyl 3-(1-(2-hydroxyphenyl)-3,5-dimethyl-1Hpyrazole-4-yl)propanoate was dissolved in 0.6 ml of methanol, and 0.29 ml of 1N sodium hydroxide was added and the mixture was stirred at room temperature for 3.5 hours. 20 ml of water was added to the reaction mixture, neutralized with 1N hydrochloric acid, and extracted with 20 ml of ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate, and the solvent was removed under reduced pressure to obtain 7.5 mg of the title compound. 1 H-NMR(CDCl3);δ(ppm) 2.29(3H, s), 2.34(3H, s), 2.56(2H, t, J=7.6Hz), 2.78(2H, t, J=7.6Hz), 6.89-6.93(1H, m), 7.08-7.10(1H, m), 7.16-7.22(2H, m). MS(FAB); m / z 261(M+H) +

[0169] Production Example 30 5-Chloro-2-(3,4,5-trimethyl-1H-pyrazole-1-yl)phenol 152 mg of the title compound was obtained from 287 mg of 2-amino-5-chlorophenol and 233 μl of 3-methyl-2,4-pentanedione by the same method as in Preparation Example 2b). 1 H-NMR(CDCl3);δ(ppm) 1.99(3H, s), 2.24(3H, s), 2.31(3H, s), 6.86-6.89(1H, m), 7.09-7.11(2H, m). MS(FAB); m / z 227(M+H) +

[0170] Manufacturing Example 31 5-amino-2-(3,5-dimethyl-1H-pyrazole-1-yl)phenol 86 mg of 2-(3,5-dimethyl-1H-pyrazole-1-yl)-5-nitrophenol was dissolved in 1.7 ml of ethanol, and 43 mg of 10% palladium / carbon was added. The mixture was stirred at room temperature for 45 minutes under a hydrogen atmosphere. After filtering out the insoluble matter, the solvent was removed under reduced pressure to obtain 30.4 mg of the title compound. 1 H-NMR(CDCl3);δ(ppm) 2.28(3H, s), 2.33(3H, s), 3.72(2H, s), 5.99(1H, s), 6.22(1H, dd, J=2.4, 8.4Hz), 6.40(1H, d, J=2.4Hz), 6.97(1H, d, J=8.4Hz), 9.27(1H, s). MS(FAB); m / z 204(M+H) +

[0171] Production Example 32 5-Nitro-2-(3,4,5-trimethyl-1H-pyrazole-1-yl)phenol 289.5 mg of the title compound was obtained from 308 mg of 2-amino-5-nitrophenol and 233 μl of 3-methyl-2,4-pentanedione by the same method as in Preparation Example 2b). 1H-NMR(CDCl3);δ(ppm) 2.02(3H, s), 2.24(3H, s), 2.40(3H, s), 7.33(1H, d, J=8.8Hz), 7.79(1H, dd, J=2.4, 8.8Hz), 7.94(1H, d, J=2.4Hz). MS(FAB); m / z 248(M+H) +

[0172] Manufacturing Example 33 4-(3,5-dimethyl-1H-pyrazole-1-yl)benzene-1,3-diol a) 2,4-dimethoxyphenylboronic acid 576 μl of 1-bromo-2,4-dimethoxybenzene was dissolved in 5.8 ml of tetrahydrofuran, and 3 ml of 1.6 mol / l n-butyllithium hexane solution was added dropwise under an argon atmosphere at -78°C. Then, 1.1 ml of triisopropyl borate was added, and the mixture was stirred at -78°C for 40 minutes, followed by stirring at room temperature for 2 hours. 40 ml of water and 1 ml of 5N hydrochloric acid were added to the reaction mixture, and the mixture was extracted with 50 ml of ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate, and the solvent was removed under reduced pressure. The compound was purified by silica gel column chromatography (hexane:ethyl acetate = 2:1) to obtain 610.2 mg of the title compound. 1 H-NMR(CDCl3);δ(ppm) 3.85(3H, s), 3.89(3H, s), 5.81(2H, s), 6.46(1H, s), 6.56(1H, dd, J=2.0, 8.4Hz), 7.77(1H, d, J=8.4Hz).

[0173] b) 1-(2,4-dimethoxyphenyl)-3,5-dimethyl-1H-pyrazole 610.2 mg of 2,4-dimethoxyphenylboronic acid was dissolved in 6 ml of methylene chloride, and 387 mg of 3,5-dimethylpyrazole, 730 mg of copper(II) acetate, and 948 μl of pyridine were added. The mixture was stirred overnight at room temperature. 60 ml of water was added to the reaction mixture, and it was extracted with 60 ml of ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate, and the solvent was removed under reduced pressure. The mixture was purified by silica gel column chromatography (hexane:ethyl acetate = 3:2) to obtain 81.7 mg of the title compound. 1 H-NMR(CDCl3);δ(ppm) 2.07(3H, s), 2.29(3H, s), 3.77(3H, s), 3.85(3H, s), 5.94(1H, s), 6.52-6.54(2H, m), 7.22-7.24(1H, m). MS(FAB); m / z 233(M+H) +

[0174] c) 4-(3,5-dimethyl-1H-pyrazole-1-yl)benzene-1,3-diol 118.4 mg of 1-(2,4-dimethoxyphenyl)-3,5-dimethyl-1H-pyrazole was dissolved in 2.3 ml of methylene chloride, and 1.7 ml of 1 M boron tribromide solution in methylene chloride was added. The mixture was stirred at room temperature for 1 hour. The reaction mixture was added to 30 ml of water, neutralized with 1N sodium hydroxide, and extracted with 50 ml of ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate, the solvent was removed under reduced pressure, and the mixture was purified using preparative thin-layer silica gel column chromatography (hexane:ethyl acetate = 1:2) to obtain 71.7 mg of the title compound. 1 H-NMR(CDCl3);δ(ppm) 2.29(3H, s), 2.33(3H,s), 6.01(1H, s), 6.37(1H, dd, J=2.8, 8.8Hz), 6.53(1H, d, J=2.8Hz), 7.03(1H, d, J=8.8Hz). MS(ESI); m / z 205(M+H) +

[0175] Manufacturing Example 34 5-amino-2-(3,4,5-trimethyl-1H-pyrazole-1-yl)phenol 118.4 mg of the title compound was obtained from 200 mg of 5-nitro-2-(3,4,5-trimethyl-1H-pyrazole-1-yl)phenol by the same method as in Preparation Example 31. 1H-NMR(CDCl3);δ(ppm) 1.97(3H, s), 2.23(3H, s), 2.24(3H, s), 3.70(2H, s), 6.22(1H, dd, J=2.4, 8.4Hz), 6.40(1H, d, J=2.4Hz), 6.95(1H, d, J=8.4Hz), 9.34(1H, s). MS(FAB); m / z 218(M+H) +

[0176] Manufacturing Example 35 4-(3,5-dimethyl-1H-pyrazole-1-yl)-3-hydroxybenzenecarboxylate methyl 239.4 mg of the title compound was obtained from 334 mg of methyl 4-amino-3-hydroxybenzenecarboxylate by the same method as in Preparation Example 2b). 1 H-NMR(CDCl3);δ(ppm) 2.31(3H, s), 2.45(3H, s), 3.92(3H, s), 6.08(1H, s), 7.26-7.29(1H, m), 7.60(1H, dd, J=1.6, 8.0Hz), 7.76(1H, d, J=1.6Hz). MS(ESI); m / z 247(M+H) +

[0177] Manufacturing Example 36 3-amino-2-(3,5-dimethyl-1H-pyrazole-1-yl)phenol 38.9 mg of the title compound was obtained from 56.6 mg of 2-(3,5-dimethyl-1H-pyrazole-1-yl)-3-nitrophenol by the same method as in Preparation Example 31. 1 H-NMR(CDCl3);δ(ppm) 2.14(3H, s), 2.25(3H, s), 3.57(2H, s), 6.02(1H, s), 6.32-6.37(2H, m), 7.02(1H, t, J=8.0Hz). MS(FAB); m / z 204(M+H) +

[0178] Production Example 37 4-(3,5-dimethyl-1H-pyrazole-1-yl)-3-hydroxybenzenecarboxylic acid 100 mg of methyl 4-(3,5-dimethyl-1H-pyrazole-1-yl)-3-hydroxybenzenecarboxylate was dissolved in 1 ml of methanol, and 1.6 ml of 1N sodium hydroxide was added and the mixture was stirred at room temperature for 3.5 hours. 20 ml of water was added to the reaction mixture, neutralized with 1N hydrochloric acid, and extracted with 20 ml of ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate, and the solvent was removed under reduced pressure to obtain 40.8 mg of the title compound. 1 H-NMR(CD3OD);δ(ppm) 2.16(3H, s), 2.24(3H, s), 6.04(1H, s), 7.30(1H, d, J=8.4Hz), 7.59(1H, dd, J=2.0, 8.4Hz), 7.64(1H, d, J=2.0Hz). MS(ESI); m / z 233(M+H) +

[0179] Manufacturing Example 38 4-(3,5-dimethyl-1H-pyrazole-1-yl)-3-hydroxy-N,N-dimethylbenzamide 36 mg of 4-(3,5-dimethyl-1H-pyrazole-1-yl)-3-hydroxybenzenecarboxylic acid was dissolved in 0.4 ml of dimethylformamide, and 36 mg of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride, 25 mg of 1-hydroxybenzotriazole, and 93 μl of dimethylamine (2.0 M THF solution) were added. The mixture was stirred at room temperature for 4 hours. 10 ml of water was added to the reaction mixture, and it was extracted with 15 ml of ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate, and the solvent was removed under reduced pressure. The compound was purified by preparative thin-layer silica gel column chromatography (ethyl acetate) to obtain 11.4 mg of the title compound. 1 H-NMR(CDCl3);δ(ppm) 2.31(3H, s), 2.41(3H, s), 3.02(3H, s), 3.11(3H, s), 6.06(1H, s), 6.97(1H, d, J=8.0Hz), 7.23(1H, d, J=8.0Hz), 7.26(1H, s). MS(ESI); m / z 259(M+H) +

[0180] Manufacturing Example 39 4-(3,5-dimethyl-1H-pyrazole-1-yl)-3-hydroxybenzamide 34.3 mg of the title compound was obtained from 73.1 mg of 4-(3,5-dimethyl-1H-pyrazole-1-yl)-3-hydroxybenzenecarboxylic acid and 38 μl of aqueous ammonia by the same method as in Preparation Example 38. 1 H-NMR(CD3OD);δ(ppm) 2.16(3H, s), 2.24(3H, s), 6.04(1H, s), 7.29(1H, d, J=8.4Hz), 7.41 (1H, dd, J=2.0, 8.4Hz), 7.50(1H, d, J=2.0Hz). MS(ESI); m / z 232(M+H) +

[0181] Production Example 40 3-Hydroxy-4-(3,4,5-trimethyl-1H-pyrazole-1-yl)benzenecarboxylic acid a) 3-hydroxy-4-(3,4,5-trimethyl-1H-pyrazole-1-yl)benzenecarboxylate methyl 110.4 mg of the title compound was obtained from 167 mg of methyl 4-amino-3-hydroxybenzenecarboxylate and 116 μl of 3-methyl-2,4-pentanedione by the same method as in Preparation Example 2b). 1 H-NMR(CDCl3);δ(ppm) 2.00(3H, s), 2.26(3H, s), 2.36(3H, s), 3.92(3H, s), 7.23-7.26(1H, m), 7.58-7.60(1H, m), 7.49(1H, s), 10.53(1H, s). MS(ESI); m / z 261(M+H) +

[0182] b) 3-Hydroxy-4-(3,4,5-trimethyl-1H-pyrazole-1-yl)benzenecarboxylic acid 68.7 mg of the title compound was obtained from 110 mg of methyl 3-hydroxy-4-(3,4,5-trimethyl-1H-pyrazole-1-yl)-benzenecarboxylate by the same method as in Preparation Example 37. 1H-NMR(CD3OD);δ(ppm) 1.99(3H, s), 2.09(3H, s), 2.20(3H, s), 7.28(1H, d, J=8.0Hz),7.59(1H, dd, J=2.0, 8.0Hz), 7.63(1H, d, J=2.0Hz). MS(ESI); m / z 247(M+H) +

[0183] Manufacturing Example 41 3-Hydroxy-4-(3,4,5-trimethyl-1H-pyrazole-1-yl)benzamide 33.3 mg of the title compound was obtained from 65 mg of 3-hydroxy-4-(3,4,5-trimethyl-1H-pyrazole-1-yl)benzenecarboxylic acid and 32 μl of aqueous ammonia by the same method as in Preparation Example 38. 1 H-NMR(CD3OD);δ(ppm) 1.99(3H, s), 2.09(3H, s), 2.19(3H, s), 7.27(1H, d, J=8.0Hz),7.40(1H, dd, J=2.0, 8.0Hz), 7.57(1H, d, J=2.0Hz). MS(ESI); m / z 246(M+H) +

[0184] Manufacturing Example 42 4-(4-chloro-3,5-dimethyl-1H-pyrazole-1-yl)-3-hydroxybenzamide a) 4-(4-chloro-3,5-dimethyl-1H-pyrazole-1-yl)-3-hydroxybenzoate methyl 69.1 mg of the title compound was obtained from 167 mg of methyl 4-amino-3-hydroxybenzoate and 114 μl of 3-chloropentan-2,4-dione by the same method as in Preparation Example 2b). 1 H-NMR(CDCl3);δ(ppm) 2.32(3H, s), 2.42(3H, s), 3.93(3H, s), 7.24-7.26(1H, m), 7.60-7.66(1H, m), 7.77(1H, s).

[0185] b) 4-(4-chloro-3,5-dimethyl-1H-pyrazole-1-yl)-3-hydroxybenzoic acid The title compound (39.2 mg) was obtained from 69.1 mg of methyl 4-(4-chloro-3,5-dimethyl-1H-pyrazol-1-yl)-3-hydroxybenzoate in the same manner as in Production Example 37. 1 H-NMR(CD3OD); δ(ppm) 2.15(3H, s), 2.24(3H, s), 7.32 - 7.35(1H, m), 7.59 - 7.66(2H, m). MS(ESI); m / z 267(M + H) +

[0186] c) 4-(4-Chloro-3,5-dimethyl-1H-pyrazol-1-yl)-3-hydroxybenzamide The title compound (12.3 mg) was obtained from 37.9 mg of 4-(4-chloro-3,5-dimethyl-1H-pyrazol-1-yl)-3-hydroxybenzoic acid and 17 μl of aqueous ammonia in the same manner as in Production Example 38. 1 H-NMR(CD3OD); δ(ppm) 2.14(3H, s), 2.24(3H, s), 7.29 - 7.32(1H, m), 7.41 - 7.44(1H, m), 7.50(1H, s). MS(ESI); m / z 266(M + H) +

[0187] Production Example 43 2-(3,5-Dimethyl-1H-pyrazol-1-yl)benzene-1,3-diol a) 2-Aminobenzene-1,3-diol 465 mg of 2-nitresorcinol was dissolved in 9.3 ml of ethanol, 230 mg of 10% palladium / carbon was added, and the mixture was stirred at room temperature for 1 hour under a hydrogen atmosphere. After filtering off the insoluble matter, the solvent was distilled off under reduced pressure to obtain 338.5 mg of the title compound. 1 H-NMR(DMSO-d6); δ(ppm) 6.20 - 6.28(3H, m). MS(ESI); m / z 126(M + H) +

[0188] b) 2-Amino-1,3-phenylene bis(4-methylbenzenesulfonate) 100 mg of 2-aminobenzene-1,3-diol was dissolved in 2 ml of dichloromethane, and 234 μl of triethylamine and 320 mg of p-toluenesulfonyl chloride were added. The mixture was stirred at room temperature for 1.5 hours. 20 ml of water was added to the reaction mixture, and it was extracted with 20 ml of ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate, and the solvent was removed under reduced pressure. The mixture was purified by silica gel column chromatography (hexane:ethyl acetate = 4:1) to obtain 278.1 mg of the title compound. 1 H-NMR(CDCl3);δ(ppm) 2.46(6H, s), 3.83(2H, s), 6.48(1H, t, J=8.1Hz), 6.79(2H, d, J=8.3Hz), 7.32(4H, d, J=8.1Hz), 7.72(4H, d, J=8.3Hz). MS(ESI); m / z 434(M+H) +

[0189] c) 2-(3,5-dimethyl-1H-pyrazole-1-yl)-3-hydroxyphenyl 4-methylbenzene sulfonate 278 mg of 2-amino-1,3-phenylene bis(4-methylbenzenesulfonate) was added to 0.64 ml of 5N hydrochloric acid, and a solution of 58 mg of sodium nitrite dissolved in 0.4 ml of water was added dropwise at 0°C, and the mixture was stirred for 30 minutes. Next, a solution of 289 mg of stannous chloride dissolved in 0.32 ml of 5N hydrochloric acid was added dropwise at 0°C, and the mixture was stirred for 1 hour. The solvent was removed under reduced pressure, and 1.3 ml of ethanol and 66 μl of acetylacetone were added, and the mixture was heated under reflux for 2 hours. 50 ml of water was added to the reaction mixture, neutralized with saturated sodium bicarbonate solution, and extracted with 50 ml of ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate, and the solvent was removed under reduced pressure. The compound was purified by silica gel column chromatography (hexane:ethyl acetate = 4:1 to 1:1) to obtain 62.9 mg of the title compound. 1H-NMR(CDCl3);δ(ppm) 2.15(3H, s), 2.17(3H, s), 2.41(3H, s), 5.91(1H, s), 6.93-6.-96(2H, m), 7.14(2H, d, J=8.0Hz), 7.18-7.26(1H, m), 7.35(2H, d, J=8.0Hz). MS(ESI); m / z 359(M+H) +

[0190] d) 2-(3,5-dimethyl-1H-pyrazole-1-yl)benzene-1,3-diol 62 mg of 2-(3,5-dimethyl-1H-pyrazole-1-yl)-3-hydroxyphenyl 4-methylbenzenesulfonate was added to a solution of 97 mg of potassium hydroxide dissolved in 1.5 ml of ethanol and 1.5 ml of water, and the mixture was heated under reflux for 3.5 hours. 20 ml of water was added to the reaction mixture, and it was extracted with 20 ml of ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate, and the solvent was removed under reduced pressure. The mixture was purified by preparative thin-layer silica gel column chromatography (hexane:ethyl acetate = 1:1) to obtain 20.8 mg of the title compound. 1 H-NMR(CDCl3);δ(ppm) 2.15(3H, s), 2.16(3H, s), 5.98(1H, s), 6.45(2H, d, J=8.4Hz), 7.00(1H, t, J=8.4Hz). MS(ESI); m / z 205(M+H) +

[0191] Manufacturing Example 44 2-(3,5-dimethyl-1H-pyrazole-1-yl)-5-methylphenol a) 2-amino-5-methylphenyl 4-methylbenzenesulfonate 400 mg of 2-amino-5-methylphenol was dissolved in 6.5 ml of dichloromethane, and 476 μl of triethylamine and 619 mg of p-toluenesulfonyl chloride were added. The mixture was stirred at room temperature for 1 hour. 60 ml of water was added to the reaction mixture, and it was extracted with 60 ml of ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate, and the solvent was removed under reduced pressure. The mixture was purified by silica gel column chromatography (hexane:ethyl acetate = 3:1) to obtain 730.1 mg of the title compound. 1 H-NMR(CDCl3);δ(ppm) 2.15(3H, s), 2.46(3H, s), 3.63(2H, brs), 6.61-6.63(1H, m), 6.67(1H, s), 6.82-6.85(1H, m), 6.33(2H, d, J=8.4Hz), 7.78(2H, d, J=8.4Hz).MS(ESI); m / z 278(M+H) +

[0192] b) 2-(3,5-dimethyl-1H-pyrazole-1-yl)-5-methylphenyl 4-methylbenzene sulfonate 453 mg of 2-amino-5-methylphenyl 4-methylbenzenesulfonate was added to 1.6 ml of 5N hydrochloric acid, and a solution of 146 mg of sodium nitrite dissolved in 1 ml of water was added dropwise at 0°C, and the mixture was stirred for 30 minutes. Next, a solution of 736 mg of stannous chloride dissolved in 0.8 ml of 5N hydrochloric acid was added dropwise at 0°C, and the mixture was stirred for 1 hour. The solvent was removed under reduced pressure, and 3.2 ml of ethanol and 167 μl of acetylacetone were added, and the mixture was heated under reflux for 2 hours. 50 ml of water was added to the reaction mixture, neutralized with saturated sodium bicarbonate solution, and extracted with 80 ml of ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate, and the solvent was removed under reduced pressure. The compound was purified by silica gel column chromatography (hexane:ethyl acetate = 2:1) to obtain 199.6 mg of the title compound. 1 H-NMR(CDCl3);δ(ppm) 2.09(3H, s), 2.11(3H, s), 2.41(3H,s), 2.43(3H, s), 5.82(1H, s), 7.15-7.21(4H, m), 7.36-7.38(3H, m). MS(ESI); m / z 357(M+H) +

[0193] c) 2-(3,5-dimethyl-1H-pyrazole-1-yl)-5-methylphenol 199.6 mg of 2-(3,5-dimethyl-1H-pyrazole-1-yl)-5-methylphenyl 4-methylbenzenesulfonate was added to a solution of 314 mg of potassium hydroxide dissolved in 4 ml of ethanol and 4 ml of water, and the mixture was heated under reflux for 1 hour. 20 ml of water was added to the reaction mixture, and it was extracted with 20 ml of ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate, and the solvent was removed under reduced pressure. The mixture was purified using preparative thin-layer silica gel column chromatography (hexane:ethyl acetate = 4:1), and the desired fraction was dissolved in 1,4-dioxane and freeze-dried to obtain 66.2 mg of the title compound. 1 H-NMR(CDCl3);δ(ppm) 2.29(3H, s), 2.33(3H,s), 2.37(3H,s), 6.01(1H, s), 6.70(1H, d, J=8.0Hz), 6.90(1H, s), 7.07(1H, d, J=8.0Hz), 9.64(1H, brs). MS(ESI); m / z 203(M+H) +

[0194] Manufacturing Example 45 2-(3,5-dimethyl-1H-pyrazole-1-yl)-5-methoxyphenol a) 2-amino-5-methoxyphenyl 4-methylbenzenesulfonate 220.1 mg of the title compound was obtained from 176 mg of 2-hydroxy-4-methoxyaniline hydrochloride by the same method as in Preparation Example 44 a). 1 H-NMR(CDCl3);δ(ppm) 2.46(3H, s), 3.62(3H, s), 6.41(1H, s), 6.65-6.66(2H, m), 7.34(2H, d, J=8.8Hz), 7.79(2H, d, J=8.8Hz).

[0195] b) 2-(3,5-dimethyl-1H-pyrazole-1-yl)-5-methoxyphenyl 4-methylbenzene sulfonate From 220 mg of 2-amino-5-methoxyphenyl 4-methylbenzenesulfonate, 93.7 mg of the title compound was obtained by the same method as in Preparation Example 44b). 1 H-NMR(CDCl3);δ(ppm) 2.08(3H, s), 2.11(3H, s), 2.41(3H, s), 3.85(3H, s), 5.82(1H, s), 6.87(1H, dd, J=2.4, 8.4Hz), 7.06(1H, d, J=2.4Hz), 7.17(2H, d, J=8.4Hz), 7.20-7.24(1H, m), 7.39(2H, d, J=8.4Hz). MS(ESI); m / z 373(M+H) +

[0196] c) 2-(3,5-dimethyl-1H-pyrazole-1-yl)-5-methoxyphenol 30.1 mg of the title compound was obtained from 93 mg of 2-(3,5-dimethyl-1H-pyrazole-1-yl)-5-methoxyphenyl 4-methylbenzenesulfonate by the same method as in Preparation Example 44c). 1 H-NMR(CDCl3);δ(ppm) 2.27(3H, s), 2.33(3H, s), 3.80(3H, s), 6.00(1H, s), 6.45(1H, dd, J=2.8, 8.4Hz), 6.61(1H, d, J=2.8Hz), 7.08(1H, d, J=8.4Hz), 9.67(1H, brs). MS(ESI); m / z 219(M+H) +

[0197] Manufacturing Example 46 2-(3,5-dimethyl-1H-pyrazole-1-yl)-3-methylphenol a) 2-amino-3-methylphenyl 4-methylbenzenesulfonate From 200 mg of 2-amino-3-methylphenol, 374.1 mg of the title compound was obtained by the same method as in Preparation Example 43b). 1 H-NMR(CDCl3);δ(ppm) 2.14(3H, s), 2.46(3H, s), 3.79(2H,s), 6.51(1H, t, J=8.0Hz), 6.63(1H, d, J=8.0Hz), 6.91(1H, d, J=8.0Hz), 7.32(2H, d, J=8.4Hz), 7.78(2H, d, J=8.4Hz). MS(ESI); m / z 278(M+H) +

[0198] b) 2-(3,5-dimethyl-1H-pyrazole-1-yl)-3-methylphenyl 4-methylbenzene sulfonate 269.9 mg of the title compound was obtained from 374 mg of 2-amino-3-methylphenyl 4-methylbenzenesulfonate by the same method as in Preparation Example 43c). 1 H-NMR(CDCl3);δ(ppm) 2.01(3H, s), 2.02(3H, s), 2.16(3H, s), 2.43(3H, s), 5.88(1H, s), 7.19-7.24(3H, m), 7.32(2H, d, J=5.2Hz), 7.51(2H, d, J=8.4Hz). MS(ESI); m / z 357(M+H) +

[0199] c) 2-(3,5-dimethyl-1H-pyrazole-1-yl)-3-methylphenol 79.2 mg of the title compound was obtained from 269 mg of 2-(3,5-dimethyl-1H-pyrazole-1-yl)-3-methylphenyl 4-methylbenzenesulfonate by the same method as in Preparation Example 43d). 1 H-NMR(CD3OD);δ(ppm) 1.92(3H, s), 2.01(3H, s), 2.24(3H, s), 6.02(1H, s), 6.79(2H, d, J=7.6Hz), 7.18(1H, t, J=7.6Hz). MS(ESI); m / z 203(M+H) +

[0200] Manufacturing Example 47 2-(3,5-dimethyl-1H-pyrazole-1-yl)-5-hydroxymethylphenol 132 mg of methyl 4-(3,5-dimethyl-1H-pyrazole-1-yl)-3-hydroxybenzenecarboxylate was dissolved in 2.6 ml of tetrahydrofuran, and 58 mg of lithium borohydride was added. The mixture was stirred at 50°C for 3.5 hours. 20 ml of water was added to the reaction mixture, and it was extracted with 20 ml of ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate, and the solvent was removed under reduced pressure. The mixture was purified by preparative thin-layer silica gel column chromatography (hexane:ethyl acetate = 1:2) to obtain 12.4 mg of the title compound. 1 H-NMR(CDCl3);δ(ppm) 2.28(3H,s), 2.44(3H, s), 4.64(2H, s), 6.02(1H, s), 6.90(1H, d, J=8.0Hz), 7.02(1H, s), 7.17(1H, d, J=8.0Hz). MS(ESI); m / z 219(M+H) +

[0201] Manufacturing Example 48 2-(3,5-dimethyl-1H-pyrazole-1-yl)-5-methylaminophenol a) 1-(2-methoxy-4-nitrophenyl)-3,5-dimethyl-1H-pyrazole From 700 mg of 2-methoxy-4-nitroaniline, 498 mg of the title compound was obtained by the same method as in Preparation Example 43c). 1 H-NMR(CDCl3);δ(ppm) 2.13(3H, s), 2.30(3H, s), 3.93(3H, s), 6.02(1H, s), 7.53(1H, d, J=8.4Hz), 7.89(1H, d, J=2.0Hz), 7.95(1H, dd, J=2.0, 8.4Hz). MS(ESI); m / z 248(M+H) +

[0202] b) 4-(3,5-dimethyl-1H-pyrazole-1-yl)-3-methoxyaniline From 495 mg of 1-(2-methoxy-4-nitrophenyl)-3,5-dimethyl-1H-pyrazole, 417.6 mg of the title compound was obtained in the same manner as in Production Example 31. 1 H-NMR(CDCl3); δ(ppm) 2.06(3H, s), 2.28(3H, s), 3.72(3H, s), 3.81(2H, brs), 5.92(1H, s), 6.28 - 6.31(2H, m), 7.06(1H, d, J = 8.4Hz). MS(ESI); m / z 218(M + H) +

[0203] c) 4-(3,5-Dimethyl-1H-pyrazol-1-yl)-3-methoxy-N-methylaniline 200 mg of 4-(3,5-dimethyl-1H-pyrazol-1-yl)-3-methoxyaniline was dissolved in 6 ml of dimethylformamide, 160 μl of methyl iodide and 636 mg of potassium carbonate were added, and the mixture was stirred at room temperature for 2.5 hours. 50 ml of water was added to the reaction mixture, and the mixture was extracted with 50 ml of ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate, and then the solvent was distilled off under reduced pressure. The residue was purified by preparative thin-layer silica gel column chromatography (hexane:ethyl acetate = 1:3) to obtain 48.7 mg of the title compound. 1 H-NMR(CDCl3); δ(ppm) 2.07(3H, s), 2.28(3H, s), 2.86(3H, s), 3.74(3H, s), 3.95(1H, brs), 5.92(1H, s), 6.17(1H, d, J = 2.4Hz), 6.21(1H, dd, J = 2.4, 8.4Hz), 7.09(1H, d, J = 8.4Hz). MS(ESI); m / z 232(M + H) +

[0204] d) 2-(3,5-Dimethyl-1H-pyrazol-1-yl)-5-methylaminophenol From 58.7 mg of 4-(3,5-dimethyl-1H-pyrazol-1-yl)-3-methoxy-N-methylaniline, 25 mg of the title compound was obtained in the same manner as in Production Example 33c). 1 H-NMR(CDCl3);δ(ppm) 2.28(3H, s), 2.32(3H, s), 2.83(3H, d, J=1.2Hz), 5.98(1H, s), 6.13-6.16(1H, m), 6.31-6.32(1H, m), 6.99(1H, dd, J=1.2, 8.4Hz). MS(ESI); m / z 218(M+H) +

[0205] Manufacturing Example 49 2-(3,5-dimethyl-1H-pyrazole-1-yl)-4-methylphenol a) 2-amino-4-methylphenyl 4-methylbenzenesulfonate From 479 mg of 2-amino-4-methylphenol hydrochloride, 770.1 mg of the title compound was obtained by the same method as in Preparation Example 43b). 1 H-NMR(CDCl3);δ(ppm) 2.21(3H, s), 2.46(3H, s), 3.74(2H, brs), 6.39(1H, d, J=8.0Hz), 6.53(1H, s), 6.62(1H, d, J=8.0Hz), 7.32(2H, d, J=8.0Hz), 7.77(2H, d, J=8.0Hz). MS(ESI); m / z 278(M+H) +

[0206] b) 2-(3,5-dimethyl-1H-pyrazole-1-yl)-4-methylphenyl 4-methylbenzene sulfonate 137.3 mg of the title compound was obtained from 400 mg of 2-amino-4-methylphenyl 4-methylbenzenesulfonate by the same method as in Preparation Example 43c). 1 H-NMR(CDCl3);δ(ppm) 2.10(3H, s), 2.12(3H, s), 2.35(3H, s), 2.41(3H, s), 5.82(1H, s), 7.13-7.15(3H, m), 7.20-7.22(1H, m), 7.33-7.36(2H, m), 7.42(2H, d, J=8.4Hz). MS(ESI); m / z 357(M+H)+

[0207] c) 2-(3,5-dimethyl-1H-pyrazole-1-yl)-4-methylphenol 60.4 mg of the title compound was obtained from 167 mg of 2-(3,5-dimethyl-1H-pyrazole-1-yl)-4-methylphenyl 4-methylbenzenesulfonate by the same method as in Preparation Example 43d). 1 H-NMR(CDCl3);δ(ppm) 2.29(3H, s), 2.31(3H, s), 2.39(3H, s), 6.02(1H, s), 6.97-7.02(3H, m), 9.43(1H, s). MS(ESI); m / z 203(M+H) +

[0208] Manufacturing Example 50 2-(3,5-dimethyl-1H-pyrazole-1-yl)-5-trifluoromethylphenol a) 1-(2-methoxy-4-(trifluoromethylphenyl)-3,5-dimethyl-1H-pyrazole) From 191 mg of 2-methoxy-4-trifluoromethylaniline, 95.5 mg of the title compound was obtained by the same method as in Preparation Example 43c). 1 H-NMR(CDCl3);δ(ppm) 2.05(3H,s), 2.30(3H, s), 3.86(3H, s), 5.99(1H,s), 7.22(1H,s), 7.31(1H, d, J=8.0Hz), 7.46(1H, d, J=8.0Hz). MS(ESI); m / z 271(M+H) +

[0209] b) 2-(3,5-dimethyl-1H-pyrazole-1-yl)-5-trifluoromethylphenol 25.7 mg of the title compound was obtained from 95.5 mg of 1-(2-methoxy-4-trifluoromethylphenyl)-3,5-dimethyl-1H-pyrazole by the same method as in Preparation Example 33c). 1H-NMR(CDCl3);δ(ppm) 2.31(3H, s), 2.45(3H, s), 6.08(1H,s), 7.15-7.18(1H, m), 7.30-7.35(2H, m), 10.64(1H,s). MS(ESI); m / z 257(M+H) +

[0210] Manufacturing Example 51 2-(3,5-dimethyl-1H-pyrazole-1-yl)-6-methylphenol a) 2-amino-6-methylphenyl 4-methylbenzenesulfonate From 200 mg of 6-amino-o-cresol hydrochloride, 159.9 mg of the title compound was obtained by the same method as in Preparation Example 43b). 1 H-NMR(CDCl3);δ(ppm) 2.06(3H, s), 2.48(3H, s), 3.96(2H, s), 6.53-6.55(1H, m), 6.59-6.61(1H, m), 6.93(1H, t, J=7.6Hz), 7.37(2H, d, J=8.0Hz), 7.90(2H, d, J=8.0Hz). MS(ESI); m / z 278(M+H) +

[0211] b) 2-(3,5-dimethyl-1H-pyrazole-1-yl)-6-methylphenyl 4-methylbenzene sulfonate 48.8 mg of the title compound was obtained from 159.5 mg of 2-amino-6-methylphenyl 4-methylbenzenesulfonate by the same method as in Preparation Example 43c). 1 H-NMR(CDCl3);δ(ppm) 2.09(3H, s), 2.10(3H, s), 2.43(3H, s), 2.49(3H, s), 5.67(1H, s), 7.13-7.32(5H, m), 7.48(2H, d, J=8.0Hz). MS(ESI); m / z 357(M+H) +

[0212] c) 2-(3,5-dimethyl-1H-pyrazole-1-yl)-6-methylphenol 12 mg of the title compound was obtained from 48.5 mg of 2-(3,5-dimethyl-1H-pyrazole-1-yl)-6-methylphenyl 4-methylbenzenesulfonate by the same method as in Preparation Example 43d). 1 H-NMR(CDCl3);δ(ppm) 2.30(3H, s), 2.31(3H, s), 2.38(3H, s), 6.03(1H, s), 6.81(1H, t, J=8.0Hz), 7.03-7.09(2H, m), 9.79(1H, s). MS(ESI); m / z 203(M+H) +

[0213] Manufacturing Example 52 2-(3,5-dimethyl-1H-pyrazole-1-yl)-5-ethylphenol a) 4-Chloro-5-ethyl-2-nitrophenyl methanesulfonate 150 mg of 4-chloro-5-ethyl-2-nitrophenol was dissolved in 1.5 ml of dichloromethane, and 156 μl of triethylamine and 69 μl of methanesulfonyl chloride were added. The mixture was stirred at room temperature for 30 minutes. 50 ml of water was added to the reaction mixture, and it was extracted with 60 ml of ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate, and the solvent was removed under reduced pressure to obtain 200.7 mg of the title compound. 1 H-NMR(CDCl3);δ(ppm) 1.28(3H, t, J=7.6Hz), 2.83(2H, q, J=7.6Hz), 3.37(3H, s), 7.42(1H, s), 8.09(1H, s).

[0214] b) 2-amino-5-ethylphenyl methanesulfonate 200 mg of 4-chloro-5-ethyl-2-nitrophenyl methanesulfonate was dissolved in 4 ml of ethanol, and 200 mg of 10% palladium / carbon was added. The mixture was stirred at room temperature under a hydrogen atmosphere for 4 hours. After filtering out the insoluble matter, the solvent was removed under reduced pressure to obtain 74.9 mg of the title compound. 1H-NMR(CD3OD);δ(ppm) 1.26(3H, t, J=7.6Hz), 2.73(2H,q, J=7.6Hz), 3.47(3H, s), 7.28-7.46(3H, m). MS(ESI); m / z 216(M+H) +

[0215] c) 2-(3,5-dimethyl-1H-pyrazole-1-yl)-5-ethylphenyl methanesulfonate From 74.5 mg of 2-amino-5-ethylphenyl methanesulfonate, 28.1 mg of the title compound was obtained by the same method as in Preparation Example 43c). 1 H-NMR(CDCl3);δ(ppm) 1.28(3H, t, J=7.6Hz), 2.17(3H, s), 2.26(3H, s), 2.65(3H, s), 2.73(2H, q, J=7.6Hz), 6.00(1H, s), 7.24-7.26(1H, m), 7.33-7.37(2H, m). MS(ESI); m / z 295(M+H) +

[0216] d) 2-(3,5-dimethyl-1H-pyrazole-1-yl)-5-ethylphenol 28 mg of 2-(3,5-dimethyl-1H-pyrazole-1-yl)-5-ethylphenyl methanesulfonate was dissolved in 0.1 ml of methanol, and 0.07 ml of 5N hydrochloric acid was added and heated under reflux for 30 minutes. 15 ml of water was added to the reaction mixture and extracted with 15 ml of ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate, and the solvent was removed under reduced pressure. The compound was purified using preparative thin-layer silica gel column chromatography (hexane:ethyl acetate = 4:1) to obtain 7.4 mg of the title compound. 1 H-NMR(CDCl3);δ(ppm) 1.24(3H, t, J=7.6Hz), 2.29(3H, s), 2.38(3H, s), 2.63(2H, q, J=7.6Hz), 6.02(1H, s), 6.73-6.75(1H, m), 6.94(1H, s), 7.10(1H, d, J=8.0Hz), 9.67(1H, s). MS(ESI); m / z 217(M+H) +

[0217] Production Example 53 2-(4-fluoro-3,5-dimethyl-1H-pyrazole-1-yl)phenol a) 1-(2-benzyloxyphenyl)-4-fluoro-3,5-dimethyl-1H-pyrazole 500 mg of 2-benzyloxyphenylhydrazine hydrochloride and 251 mg of 3-fluoropentane-2,4-dione were added to 12 ml of ethanol and heated under reflux for 1.5 hours. The reaction mixture was concentrated under reduced pressure and purified using silica gel column chromatography (hexane:ethyl acetate = 6:1 to 5:1) to obtain 417 mg of the title compound. 1 H-NMR(CDCl3);δ(ppm) 2.07(3H, s), 2.30(3H, s), 5.04(2H, s), 7.03-7.07(2H, m), 7.24-7.37(7H, m). MS(ESI); m / z 297(M+H) +

[0218] b) 2-(4-fluoro-3,5-dimethyl-1H-pyrazole-1-yl)phenol 416 mg of 1-(2-benzyloxyphenyl)-4-fluoro-3,5-dimethyl-1H-pyrazole was dissolved in 16 ml of methanol, and 42.6 mg of 10% palladium / carbon was added. The mixture was stirred at room temperature under a hydrogen atmosphere for 24 hours. After filtering out the insoluble matter, the filtrate was removed under reduced pressure, and the resulting residue was purified using silica gel column chromatography (hexane:ethyl acetate = 5:1) to obtain 290 mg of the title compound. 1 H-NMR(CDCl3);δ(ppm) 2.28(3H, s), 2.33(3H, s), 6.90(1H, t, J=8.0Hz), 7.06(1H, d, J=8.0Hz), 7.15(1H, d, J=8.0Hz), 7.19(1H, t, J=8.0Hz). MS(ESI); m / z 207(M+H) +

[0219] Manufacturing Example 54 5-bromo-2-(3,5-dimethyl-1H-pyrazole-1-yl)phenol a) 5-bromo-2-hydrazinylphenol 4-methylbenzenesulfonate 1.0 g of 2-amino-5-bromophenol was suspended in 7 ml of ethanol, and 1.5 ml of concentrated hydrochloric acid was added dropwise at -10°C. Then, 636 mg of tert-butyl nitrite was added dropwise at the same temperature, and the mixture was stirred for 1 hour to obtain a diazonium salt solution. In a separate flask, 2.49 g of stannous chloride dihydrate, 1.08 g of p-toluenesulfonic acid monohydrate, and 15 ml of ethanol were added, and the mixture was stirred at -10°C for 15 minutes. To this solution, the previously prepared diazonium salt solution was added dropwise at -10°C, and the mixture was stirred for 1 hour. 30 ml of tert-butyl methyl ether was added, and after stirring for 15 minutes, the resulting precipitate was filtered to obtain 0.9 g of the title compound.

[0220] b) 5-bromo-2-(3,5-dimethyl-1H-pyrazole-1-yl)phenol 0.9 g of 5-bromo-2-hydrazinylphenol 4-methylbenzenesulfonate and 0.8 g of acetylacetone were added to 25 ml of ethanol and heated under reflux for 1 hour. After cooling to room temperature, the mixture was concentrated under reduced pressure, and the resulting residue was dissolved in 50 ml of ethyl acetate and washed twice with 20 ml of saturated sodium bicarbonate solution. The organic layer was dehydrated with anhydrous sodium sulfate, and the residue obtained by concentration under reduced pressure was purified by silica gel column chromatography (hexane:ethyl acetate = 4:1) to obtain 650 mg of the title compound. 1H-NMR(CDCl3); δ(ppm) 2.30(3H, s), 2.40(3H, s), 6.05(1H, s), 7.01-7.08(2H, m), 7.26(1H, s). MS(ESI); m / z 267(M+H) +

[0221] Manufacturing Example 55 5-Bromo-2-(4-chloro-3,5-dimethyl-1H-pyrazole-1-yl)phenol 558 mg of the title compound was obtained from 0.9 g of 5-bromo-2-hydrazinylphenol 4-methylbenzenesulfonate and 1.07 g of 3-chloropentan-2,4-dione, prepared in the same manner as in Preparation Example 54a), by the same method as in Preparation Example 54b). 1H-NMR(CDCl3); δ(ppm) 2.30(3H, s), 2.38(3H, s), 7.02-7.08(2H, m), 7.27(1H, d, J=2.0Hz), 9.62(1H, s). MS(ESI); m / z 303(M+H) +

[0222] Production Example 56 5-bromo-2-(3,4,5-trimethyl-1H-pyrazole-1-yl)phenol 320 mg of the title compound was obtained from 0.9 g of 5-bromo-2-hydrazinylphenol 4-methylbenzenesulfonate and 0.9 g of 3-methylpentane-2,4-dione, prepared in the same manner as in Preparation Example 54a), by the same method as in Preparation Example 54b). 1H-NMR(CDCl3); δ(ppm) 1.98(3H, s), 2.24(3H, s), 2.31(3H, s), 7.00-7.06(2H, m), 7.25(1H, d, J=1.6 Hz)), 10.34(1H, s). MS(ESI); m / z 281(M+H) +

[0223] Manufacturing Example 57 4-(3,5-dimethyl-1H-pyrazole-1-yl)-3-hydroxyphenyl acetate a) 4-nitro-1,3-phenylene diacetate Under a nitrogen atmosphere, 5.0 g of 4-nitrobenzene-1,3-diol was dissolved in 50 ml of methylene chloride, and 5.35 g of pyridine, 0.39 g of 4-dimethylaminopyridine, and 8.12 g of acetic anhydride were added sequentially under ice cooling. The mixture was heated to room temperature and stirred for 1 hour. The reaction mixture was sequentially washed with 50 ml of water, 100 ml of 1N hydrochloric acid, 100 ml of saturated sodium bicarbonate solution, and 100 ml of saturated saline solution. After dehydration with anhydrous sodium sulfate, the mixture was concentrated under reduced pressure to obtain 7.4 g of the title compound. 1H-NMR(CDCl3); δ(ppm) 2.33(3H, s), 2.37(3H, s), 7.09(1H, d, J=2.4 Hz), 7.18(1H, dd, J=2.4, 9.2 Hz), 8.16(1H, d, J=9.2 Hz).

[0224] b) 3-Hydroxy-4-nitrophenyl acetate Under a nitrogen atmosphere, 1.0 g of 4-nitro-1,3-phenylene diacetate was dissolved in 25 ml of chloroform, and 2.23 g of aluminum chloride was added under ice cooling. The mixture was heated to room temperature and stirred for 3 hours. 100 ml of water was added, and the mixture was extracted three times with 30 ml of methylene chloride. The organic layers were combined and washed sequentially with 25 ml of 1N hydrochloric acid and 25 ml of saturated brine. After dehydration with anhydrous sodium sulfate, the mixture was concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (hexane:ethyl acetate = 20:1) to obtain 610 mg of the title compound. 1H-NMR(CDCl3):δ(ppm) 2.32(3H, s), 6.77(1H, dd, J=2.4 Hz, J=9.2 Hz), 6.95(1H, d, J=2.4 Hz), 8.14(1H, d, J=9.2 Hz), 10.70(1H, s). MS (ESI); m / z 196 (MH) -

[0225] c) 4-amino-3-hydroxyphenyl acetate 3.0 g of 3-hydroxy-4-nitrophenyl acetate was dissolved in 50 ml of ethyl acetate, and 300 mg of 10% palladium / carbon was added. The mixture was stirred at room temperature under a hydrogen atmosphere for 10 hours. After filtering out the insoluble matter, the filtrate was removed under reduced pressure, and the resulting residue was purified by silica gel column chromatography (hexane:ethyl acetate = 1:1) to obtain 2.48 g of the title compound. 1H-NMR(DMSO-d6); δ(ppm) 2.17(3H, s), 4.45(2H, brs), 6.28(1H, dd, J=2.4, 8.4Hz), 6.40(1H, d, J=2.4Hz), 6.53(1H, d, J=8.4Hz), 9.26(1H, brs). MS(ESI); m / z 167(M+ )

[0226] d) 4-(3,5-dimethyl-1H-pyrazole-1-yl)-3-hydroxyphenyl acetate Using 1.0 g of 4-amino-3-hydroxyphenyl acetate, 330 mg of the title compound was obtained from 0.9 g of 4-hydrazinyl-3-hydroxyphenyl acetate 4-methylbenzenesulfonate and 0.9 g of acetylacetone, prepared in the same manner as in Preparation Example 54a), by the same method as in Preparation Example 54b). 1H-NMR(CDCl3); δ(ppm) 2.29(3H, s), 2.30(3H, s), 2.41(3H, s), 6.04(1H, s), 6.68(1H, dd, J=2.4, 8.8Hz), 6.85(1H, d, J=2.4Hz), 7.19(1H, d, J=8.8 Hz), 10.14(1H, s). MS(ESI); m / z 247(M+H) +

[0227] Manufacturing Example 58 4-(4-chloro-3,5-dimethyl-1H-pyrazole-1-yl)-3-hydroxyphenyl acetate Using 1.0 g of 4-amino-3-hydroxyphenyl acetate, 0.9 g of 4-hydrazinyl-3-hydroxyphenyl acetate 4-methylbenzenesulfonate and 1.2 g of 3-chloropentane-2,4-dione were prepared in the same manner as in Preparation Example 54a), from which 30 mg of the title compound was obtained by the same method as in Preparation Example 54b). 1H-NMR(CDCl3); δ(ppm) 2.30(3H, s), 2.31(3H, s), 2.39(3H, s), 6.70(1H, dd, J=2.8, 8.8Hz), 6.86(1H, d, J=2.8Hz), 7.17(1H, d, J=8.8 Hz), 9.50(1H, s). MS(ESI); m / z 281(M+H) +

[0228] Manufacturing Example 59 3-Hydroxy-4-(3,4,5-trimethyl-1H-pyrazole-1-yl)phenyl acetate Using 1.0 g of 4-amino-3-hydroxyphenyl acetate, 0.6 g of 4-hydrazinyl-3-hydroxyphenyl acetate 4-methylbenzenesulfonate and 1.0 g of 3-methylpentane-2,4-dione were prepared in the same manner as in Preparation Example 54a), and 230 mg of the title compound was obtained by the same method as in Preparation Example 54b). 1H-NMR(CDCl3); δ(ppm) 1.99(3H, s), 2.24(3H, s), 2.30(3H, s), 2.32(3H, s), 6.66(1H, dd, J=2.8, 8.4Hz), 6.83(1H, d, J=2.8Hz), 7.17(1H, d, J=8.4 Hz), 10.22(1H, s). MS(ESI); m / z 261(M+H) +

[0229] Manufacturing Example 60 2-(3,5-dimethyl-1H-pyrazole-1-yl)-4-methoxy-5-methylphenol a) 1,4-dimethoxy-2-methyl-5-nitrobenzene 6.0 g of 2,5-dimethoxytoluene was dissolved in 20 ml of acetic acid, and 4.32 g of fuming nitric acid (d=1.50) in 10 ml of acetic acid solution was added dropwise over 5 minutes at 40°C. The mixture was stirred at the same temperature for 30 minutes, cooled to room temperature, and stirred for another 30 minutes. The reaction mixture was diluted with 300 ml of cold water, the resulting precipitate was filtered, and washed with 100 ml of cold water. The precipitate was dried under reduced pressure to obtain 7.5 g of the title compound. 1H-NMR(CDCl3); δ(ppm) 2.28(3H, s), 3.84(3H, s), 3.92(3H, s), 6.90(1H, s), 7.40(1H, s). MS(ESI); m / z 198(M+H) +

[0230] b) 4-Methoxy-5-methyl-2-nitrophenol A 30 ml solution of methylene chloride containing 6.0 g of 1,4-dimethoxy-2-methyl-5-nitrobenzene was cooled to -20°C, and 30 ml of a 1 M solution of boron trichloride in methylene chloride was added dropwise at the same temperature. After raising the temperature to room temperature, the mixture was stirred for 16 hours, and the reaction mixture was added to 50 ml of saturated sodium bicarbonate solution. The mixture was extracted three times with 100 ml of ethyl acetate. The organic layers were combined, washed with 100 ml of water and 50 ml of saturated brine, dehydrated with anhydrous sodium sulfate, and concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (hexane:ethyl acetate = 9:1) to obtain 4.25 g of the title compound. 1H-NMR(CDCl3); δ(ppm) 2.26(3H, s), 3.84(3H, s), 6.94(1H, s), 7.39(1H, s), 10.46(1H, s). MS (ESI); m / z 182 (MH) -

[0231] c) 4-Methoxy-5-methyl-2-nitrophenyl 4-methylbenzenesulfonate Under a nitrogen atmosphere, 8.0 g of 4-methoxy-5-methyl-2-nitrophenol was dissolved in 80 ml of methylene chloride, to which 9.15 g of p-toluenesulfonyl chloride was added at room temperature and cooled to 0°C. 4.86 g of triethylamine was added and the mixture was stirred for 2 hours. The reaction mixture was poured into 150 ml of water and extracted with 150 ml of methylene chloride. The organic layer was washed with 100 ml of water and 50 ml of saturated brine, dehydrated with anhydrous sodium sulfate, and concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (hexane:ethyl acetate = 9:1) to obtain 12.0 g of the title compound. 1H-NMR(CDCl3); δ(ppm) 2.26(3H, s), 2.46(3H, s), 3.87(3H, s), 7.19(1H, s), 7.33(1H, s), 7.34(2H, d, J=8.4Hz), 7.77(2H, d, J=8.4Hz). MS (ESI); m / z 336 (MH) -

[0232] d) 2-amino-4-methoxy-5-methylphenyl 4-methylbenzenesulfonate Using 4.0 g of 4-methoxy-5-methyl-2-nitrophenyl 4-methylbenzenesulfonate, 3.2 g of the title compound was obtained by the same method as in Preparation Example 57c). 1H-NMR(DMSO-d6); δ(ppm) 1.91(3H, s), 2.41(3H, s), 3.64(3H, s), 4.73(2H, brs), 6.25(1H, s), 6.64(1H, s), 7.43(2H, d, J=8.4Hz), 7.79(2H, d, J=8.4Hz). MS(ESI); m / z 308(M+H) +

[0233] e) 2-(3,5-dimethyl-1H-pyrazole-1-yl)-4-methoxy-5-methylphenyl 4-methylbenzene sulfonate Using 1.0 g of 2-amino-4-methoxy-5-methylphenyl 4-methylbenzenesulfonate, 400 mg of the title compound was obtained by the same method as in Preparation Examples 54a) and 54b). 1H-NMR(CDCl3); δ(ppm) 2.10(6H, s), 2.25(3H, s), 2.41(3H, s), 3.79(3H, s), 5.80(1H, s), 6.71(1H, s), 7.15(2H, d, J=8.4Hz), 7.27(1H, s), 7.35(2H, d, J=8.4Hz). MS(ESI); m / z 387(M+H) +

[0234] f) 2-(3,5-dimethyl-1H-pyrazole-1-yl)-4-methoxy-5-methylphenol Using 200 mg of 2-(3,5-dimethyl-1H-pyrazole-1-yl)-4-methoxy-5-methylphenyl 4-methylbenzenesulfonate, 70 mg of the title compound was obtained by the same method as in Preparation Example 29. 1H-NMR(CDCl3); δ(ppm) 2.21(3H, s), 2.29(3H, s), 2.39(3H, s), 3.78(3H, s), 6.02(1H, s), 6.67(1H, s), 6.89(1H, s), 8.87(1H, s). MS(ESI); m / z 233(M+H) +

[0235] Production Example 61 4-Chloro-2-(3,5-dimethyl-1H-pyrazole-1-yl)-5-methylphenol a) 2-amino-4-chloro-5-methylphenol 5.0 g of 4-chloro-5-methyl-2-nitrophenol was added to 100 ml of methanol, and 8.71 g of hydrochloric acid-activated zinc powder and 7.1 g of ammonium chloride were added to 20 ml of water at 0°C. This suspension was stirred at room temperature for 4 hours, and the insoluble matter was filtered through Celite and washed with 100 ml of ethyl acetate. The filtrate and washings were combined and concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (hexane:ethyl acetate = 3:2) to obtain 1.4 g of the title compound. 1H-NMR(DMSO-d6); δ(ppm) 2.10(3H, s), 4.57(2H, brs), 6.54(1H, s), 6.58(1H, s), 9.11(1H, s). MS (ESI); m / z 157 (M) +

[0236] b) 4-Chloro-2-(3,5-dimethyl-1H-pyrazole-1-yl)-5-methylphenol Using 1.0 g of 2-amino-4-chloro-5-methylphenol, 120 mg of the title compound was obtained by the same method as in Preparation Examples 54a) and 54b). 1H-NMR(CDCl3); δ(ppm) 2.29(3H, s), 2.34(3H, s), 2.41(3H, s), 6.03(1H, s), 6.96(1H, s), 7.19(1H, s), 9.88(1H, s). MS(ESI); m / z 237(M+H) +

[0237] Manufacturing Example 62 2-(3,5-dimethyl-1H-pyrazole-1-yl)-4,5-dimethylphenol Using 1.0 g of 2-amino-4,5-dimethylphenol, 630 mg of the title compound was obtained by the same method as in Preparation Examples 54a) and 54b). 1H-NMR(CDCl3); δ(ppm) 2.21(3H, s), 2.24(3H, s), 2.29(3H, s), 2.38(3H, s), 6.00(1H, s), 6.88(1H, s), 6.94(1H, s), 9.28(1H, s). MS(ESI); m / z 217(M+H) +

[0238] Manufacturing Example 63 4-(4-chloro-3,5-dimethyl-1H-pyrazole-1-yl)-benzene-1,3-diol In Production Example 58, 200 mg of the title compound was obtained as a byproduct during silica gel column chromatography purification. 1H-NMR(CD3OD); δ(ppm) 2.07(3H, s), 2.20(3H, s), 6.36(1H, dd, J=2.4, 8.4Hz), 6.42(1H, d, J=2.4Hz), 6.98(1H, d, J=8.4Hz). MS(ESI); m / z 239(M+H) +

[0239] 2. Production example of the topical liquid preparation of the present invention Example 1 The present invention will be described below with reference to examples, but the present invention is not limited to these examples. In the following, "Production Example 44" means "the compound of Production Example 44". Production example 44 10 g Copolyvidone 10 g 100mL Ethanol The formulation was obtained by sequentially dissolving the ingredients from Production Example 44 and copovidone in a portion of ethanol, and then adding ethanol to a total volume of 100 mL. Furthermore, using the method described above, a topical solution containing the following polymer instead of copolyvidone was prepared.

[0240] 3. Appropriate formulation of the topical liquid preparation of the present invention (confirmation of stability by residual rate) Manufacturing Example 44 (1 w / v%) and various additives (5 w / v%) were dissolved in ethanol (or ethanol / ethyl acetate mixture (7:3)), placed in glass vials, and sealed. A storage test was then conducted. After storage at 40°C / 75% RH for 3 months, as shown in Table 1, the remaining percentage of Manufacturing Example 44 was 90% or higher in all cases, and no additives were found to reduce the remaining percentage of Manufacturing Example 44.

[0241]

[0242] 4. Confirmation of the drug precipitation prevention effect of the topical liquid preparation of the present invention To prevent the drug from precipitation on the nail when the topical solution of the present invention is applied to the nail, the compatibility of the drug and polymer was evaluated by differential scanning calorimetry (DSC). The polymer and drug were dissolved in ethanol in various ratios, and 50 μL of the solution was dropped into an aluminum pan for DSC and dried at 60°C for 1 hour. The dried material (film) was measured using a differential scanning calorimetry (DSC measurement conditions: crimped pan, measurement range 40°C to 120°C, heating rate 3°C / min for the powder of Production Example 44, 5°C / min for other samples, n=1). For each sample, the enthalpy of the melting peak of Production Example 44 around 105°C was calculated and compared with the melting enthalpy measured when Production Example 44 powder was measured alone. As shown in Table 2, for all polymers, a tendency was observed for the amount of drug present in a crystalline state within the film to decrease as the amount of polymer added relative to the amount of drug increased.

[0243]

[0244] 5. Evaluation of the nail permeability of the topical liquid preparation of the present invention The permeability of the topical solution of the present invention to the nails was investigated using bovine hoofs.

[0245] 1) Preparation of the test formulation

[0246]

[0247] 2) Preparation of beef hoof slices Cut a cow's hoof, 0.1 mm thick, to a suitable size and soak it in rubbing alcohol. After drying, place a cylindrical piece of plastic (approximately 2.5 mm high, 5 mm wide, and 1 mm thick) on top of the cow's hoof, secure it with adhesive, and leave it overnight to allow it to fully bond.

[0248] 3) Method After autoclaving 1% low-melting-point agarose, 80 mL portions are dispensed into petri dishes and allowed to solidify. From these solidified portions, a cylindrical agarose piece is extruded using a metal cork hole borer (approximately 1.5 cm high, 2 cm in diameter, and 5 mL in volume), and a cow's hoof with plastic attached is placed on top. 1 μL of the prepared test formulation is applied to the cow's hoof inside the cylindrical plastic container, the top is covered with Parafilm, and the mixture is left at 28°C for 7 days before the cow's hoof is removed. 35 mL of distilled water is added to the low-melting-point agarose, and the gel is dissolved at 70°C. The amount of gel permeated through the hoof of Preparation Example 44 is then quantified by LC-MS.

[0249] 4) Results As shown in Table 4, the high nail permeability of manufacturing example 44 was observed in all test formulations.

[0250]

[0251] 6. Evaluation of the quick-drying properties of the topical liquid preparation of the present invention

[0252]

[0253] 7. Sensory evaluation of the formulation The test formulations shown in Table 6 were applied to nails, and a sensory evaluation of their usability was conducted. In the sensory evaluation, the overall usability was assessed from the perspectives of stickiness, quick-drying properties, and the appearance of the film (presence or absence of drug deposition).

[0254] 8. Antifungal activity test The antifungal activity of the compound of general formula (I) contained in the topical solution of the present invention was measured by the following method. The evaluation compound was dissolved in dimethyl sulfoxide (DMSO) before use. RPMI1640 medium containing 0.165 M 3-morpholinopropanesulfonic acid (MOPS) was used as the test medium. Trichophyton mentagrophytes ATCC18748 or Trichophyton rubrum ATCC10218 were used as the test bacteria. 1 × 10⁶ of the test bacterial species were used. 4 100 μl of the compound at a concentration of conidia / ml was dispensed and mixed with the evaluation compound on a 96-well half-area plate to a DMSO concentration of 1%. The cells were incubated at 28°C for 3 days (Trichophyton mentagrophytes) or 4 days (Trichophyton rubrum). Subsequently, 5 μl of Cell Counting Kit 8 (WST8) was added, and the absorbance at 450 nm and 595 nm was measured and used as the background value. Then, the cells were incubated at 28°C for 5 hours (Trichophyton mentagrophytes) or overnight (Trichophyton rubrum) to allow color development. The absorbance at 450 nm and 595 nm was measured again, and the growth inhibition rate was calculated from the difference with the background value. The MIC value (μg / ml) was defined as the 80% growth inhibition concentration.

[0255]

[0256] 9. Antifungal activity of topical solutions The permeable anti-dermatophyte activity of the topical solution of the present invention against human nails was measured as follows using MedPharma's Tartube model. First, the test formulation was prepared. The test formulation was the topical solution formulation of Production Example 44, and was prepared by adding copovidone (10%) and ethanol to Production Example 44 at concentrations of 0% (placebo), 2%, 5%, 10%, and 15%. After applying 2 μl of the test formulation to a human fingernail on the upper part of a tar-tube cell, the tar-tube cell was cultured at 20°C to 25°C for 7 days. Subsequently, the inhibition zone length for the growth of Trichophyton rubrum inoculated on agar in the lower receiver of the tar-tube cell was measured to confirm the antifungal activity of the test formulation that permeated the human fingernail. As a result, the topical solution in manufacturing example 44 formed a zone of inhibition of a size dependent on the concentration of the active substance (2%, 5%, 10%, and 15%). On the other hand, when clinical formulations of cyclopirox and amorolfine were applied, no zone of inhibition was formed at all. Based on the above findings, it was determined that the topical solution of this invention penetrates human nails and exhibits anti-dermatophyte activity in a concentration-dependent manner.

[0257]

[0258] 10. Antifungal activity of topical solutions The permeable anti-dermatophyte activity of the topical solution of the present invention against bovine nails was measured as follows. 2 μL of the prepared test formulation was applied to a 0.1 mm thick bovine nail prepared in 5(2) inside a cylindrical plastic container, covered with Parafilm, and then placed on an agar plate inoculated with Trichophyton mentagrophytes ATCC18748 as the test bacterium. Trichophyton mentagrophytes was cultured at a culture temperature of 28°C for 4 days. Subsequently, the inhibition zone length for its growth was measured to confirm the anti-dermatophyte activity of the test formulation that permeated the bovine nail.

[0259]

[0260] Result From the evaluation results in items 2 to 10 above, it was confirmed that the topical solution containing the active ingredient, general formula (I), and the polymer, easily forms a film when applied to the skin, possesses strong antifungal activity, and exhibits high stability, nail permeability, and an inhibitory effect on the precipitation of the active ingredient. It also dries quickly, and both water-soluble and water-insoluble polymers were shown to be preferable as additive polymers. Copolyvidone, povidone, acrylic resin alkanolamine, and aminoalkyl methacrylate copolymers are particularly preferred. Furthermore, it is also preferable to add a viscosity enhancer, with silicone derivatives being particularly preferred.

[0261] The present invention provides a topical solution for nails and / or skin that has antifungal activity and high nail permeability.

Claims

[1] A film-forming agent and a general formula (wherein R b , 1-6 , 8 , 1-3 , 1-6 , 1-6 , 1-6 , , 1-6 , a , a , 2 , 1-6 , 7 , represents a hydrogen atom, C 1-6 alkyl, or trifluoromethyl, R 2 represents a hydrogen atom, C 1-6 alkyl, halogen, -COO(C 1-6 alkyl), or (CH 2 ) 1-3 COOR (R represents a hydrogen atom or C 1-6 alkyl), R 3 represents a hydrogen atom, C 1-6 alkyl, amino, trifluoromethyl, or OR (R represents a hydrogen atom or C 1-6 alkyl), R 4 represents a hydroxyl group, R 5 represents a hydrogen atom, C 1-6 alkyl, a hydroxyl group, or halogen, R 6 represents a hydrogen atom, C 1-6 alkyl, trifluoromethyl, halogen, amino, -NR a R b nitro, hydroxy C 1-6 alkyl, -CONR a R b -COO(C 1-6 alkyl), -COOH, -(CH 2 ) 1-3 COOR, or OR a (R represents a hydrogen atom or C 1-6 alkyl, and R a and R b may be the same or different and represent a hydrogen atom, C 1-6 alkyl, or C 1-6 acyl), R 7 represents a hydrogen atom, C 1-6 alkyl, -OR (R represents a hydrogen atom or C 1-6 alkyl), or halogen, R 8 represents a hydrogen atom, C 1-6 (Represents alkyl, hydroxyl, amino, or nitro groups.) A topical solution for nails and / or skin for the prevention or treatment of tinea infection, comprising a compound represented by or a salt thereof. [2] R 1 However, hydrogen atoms or C 1-6 It is alkyl, R 2 However, hydrogen atoms, C 1-6 Alkyl, halogen, or -(CH 2 ) 1-3 COOR (where R is a hydrogen atom or C) 1-6 (represents alkyl) R 3 However, hydrogen atoms, or C 1-6 It is alkyl, R 4 However, it is a hydroxyl group, R 5 However, it is a hydrogen atom, R 6 However, hydrogen atoms, C 1-6 Alkyl, trifluoromethyl, halogen, amino, -NR a R b nitro, hydroxy C 1-6 Alkyl, -CONR a R b , -COOH, or OR a (R a and R b They may be the same or different, and include hydrogen atoms and C 1-6 Alkyl, or C 1-6 (represents acyl) R 7 However, it is a hydrogen atom, R 8 However, hydrogen atoms, C 1-6 It is alkyl, amino, or nitro. A topical solution for nails and / or skin according to claim 1, comprising a compound represented by general formula (I) or a salt thereof. [3] R 1 However, C 1-6 It is alkyl, R 2 However, hydrogen atoms, C 1-6 Alkyl or halogen, R 3 However, C 1-6 It is alkyl, R 4 However, it is a hydroxyl group, R 5 However, it is a hydrogen atom, R 6 However, hydrogen atoms, C 1-6 Alkyl, halogen, or OR a (R a C is a hydrogen atom. 1-6 Alkyl, or C 1-6 (represents acyl) R 7 However, it is a hydrogen atom, R 8 However, it is a hydrogen atom. A topical solution for nails and / or skin according to claim 1, comprising a compound represented by general formula (I) or a salt thereof. [4] R 1 However, C 1-6 It is alkyl, R 2 However, it is a hydrogen atom, R 3 However, C 1-6 It is alkyl, R 4 However, it is a hydroxyl group, R 5 However, it is a hydrogen atom, R 6 However, C 1-6 It is alkyl, R 7 However, it is a hydrogen atom, R 8 The topical solution for nails and / or skin according to claim 1, wherein the compound represented by general formula (I), which is a hydrogen atom, or a salt thereof. [5] The topical solution for nails and / or skin according to claim 1, comprising 2-(3,5-dimethyl-1H-pyrazole-1-yl)-5-methylphenol. [6] The topical solution for nails and / or skin according to any one of claims 1 to 5, wherein the film-forming agent comprises a polymer. [7] The topical solution for nails and / or skin according to claim 6, wherein the polymer is copolyvidone, povidone, acrylic resin alkanolamine, or aminoalkyl methacrylate copolymer. [8] A topical solution for nails and / or skin according to any one of claims 1 to 7, comprising a lower alcohol. [9] A topical solution for nails and / or skin according to any one of claims 1 to 8, comprising a viscosity agent. [10] The topical solution for nails and / or skin according to claim 9, wherein the viscosity agent is a silicone derivative, hydrophobized hydroxypropyl methylcellulose, or poloxamer. [11] A topical solution for nails and / or skin according to any one of claims 1 to 10, comprising a compound represented by general formula (I) or a salt thereof in an amount of 1 to 30% by mass relative to the total volume of the solution. [12] A topical solution for nails and / or skin according to any one of claims 1 to 10, comprising a compound represented by general formula (I) or a salt thereof in a proportion of 1 to 20% by mass relative to the total amount of the solution. [13] A topical solution for nails and / or skin according to any one of claims 1 to 10, comprising a compound represented by general formula (I) or a salt thereof in an amount of 5 to 15% by mass relative to the total volume of the solution. [14] A topical solution for nails and / or skin according to any one of claims 1 to 13, for the prevention or treatment of onychomycosis.